Choroby a jejich příznaky

Stárnutí/opatření proti stárnutí

1. Schulz, T. J., Zarse, K., Voigt, A., Urban, N., Birringer, M., Ristow, M. 2007 (Oct). „Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress“. Cell Metab. 6(4):280–293.

2. Aliev, G., Liu, J., Shenk, J. C., Fischbach, K., Pacheco, G. J., Chen, S. G., Obrenovich, M. E., Ward, W. F., Richardson, A. G., Smith, M. A., Gasimov, E., Perry, G., Ames, B. N. 2009 (Feb). „Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats“. J Cell Mol Med. 13(2):320–333.

3. Baker, Darren J., Tobias Wijshake, Tamar Tchkonia, Nathan K. LeBrasseur, Bennett G. Childs, Bart van de Sluis, James L. Kirkland, Jan M. van Deursen. 2011. „Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders“. Nature 479:232–236.

4. Marchalant, Y., Brothers, H. M., Norman, G. J., Karelina, K., DeVries, A. C., Wenk, G. L. 2009 (May). „Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis“. Neurobiol Dis. 34(2):300–307.

5. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., Mitchell, R. L. 1995 (Sept). „Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors“. Mol Pharmacol. 48(3):443–450.

6. Ostir, G. V., Markides, K. S., Black, S. A., Goodwin, J. S. 2000 (May). „Emotional well-being predicts subsequent functional independence and survival“. J Am Geriatr Soc. 48(5):473–478.

7. Antonio Terracciano, Ph.D., Corinna E. Löckenhoff, Ph.D., Alan B. Zonderman, Ph.D., Luigi Ferrucci, M.D., Ph.D., Paul T. Costa, Jr., Ph.D. 2008. „Personality predictors of longevity: Activity, emotional stability, and conscientiousness“. Psychosomatic Medicine 70:621–627.

8. Danner, D. D., Snowdon, D. A., Friesen, W. V. 2001 (May). „Positive emotions in early life and longevity: Findings from the nun study“. Pers Soc Psychol. 80(5):804–813.

9. Jacobs, T. L., Epel, E. S., Lin, J., Blackburn, E. H., Wolkowitz, O. M., Bridwell, D. A., Zanesco, A. P., Aichele, S. R., Sahdra, B. K., MacLean, K. A., King, B. G., Shaver, P. R., Rosenberg, E. L., Ferrer, E., Wallace, B. A., Saron, C. D. 2011 (Jun). „Intensive meditation training, immune cell telomerase activity, and psychological mediators“. Psychoneuroendocrinology 36(5):664–681.

10. Horváth, Béla, Partha Mukhopadhyay, Malek Kechrid, Vivek Patel, Gali Tanchian, David A. Wink, Jürg Gertsch, Pál Pacher. 2012 (April 15). „β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner“. Free Radical Biology and Medicine 52(8):1325–1333.

Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J. Z., Xie, X. Q., Altmann, K. H., Karsak, M., Zimmer, A. 2008 (Jul 1). „Beta-caryophyllene is a dietary cannabinoid“. Proc Natl Acad Sci USA 105(26):9099–9104.

Anorexie a kachexie

1. Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., Cerny, T. 2006. „Comparison of orally administered cannabis extract and delta-9 tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group“. J Clin Oncol 24(21):3394–3400.

2. Gómez, R., Navarro, M., Ferrer, B., Trigo, J. M., Bilbao, A., Del Arco, I., Cippitelli, A., Nava, F., Piomelli, D., Rodríguez de Fonseca, F. 2002 (Nov 1). „A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding“. J Neurosci. 22(21):9612–9617.

3. Wilson, M. M., Philpot, C., Morley, J. E. 2007 (Mar-Apr). „Anorexia of aging in long-term care: Is Dronabinol an effective appetite stimulant?—a pilot study“. J Nutr Health Aging 11(2):195–198.

4. Jo, Y. H., Chen, Y. J., Chua, S. C., Jr., Talmage, D. A., Role, L. W. 2005 (Dec 22). „Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit“. Neuron 48(6):1055–1066.

5. Dejesus, E., Rodwick, B. M., Bowers, D., Cohen, C. J., Pearce, D. 2007. „Use of Dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients“. J Int Assoc Physicians AIDS Care 6(2):95–100.

6. Kirkham, T. C. 2005 (Sep). „Endocannabinoids in the regulation of appetite and body weight“. Behav Pharmacol. 16(5-6):297–313.

7. Costiniuk, C. T., Mills, E., Cooper, C. L. 2008 (Apr). „Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus“. Can J Gastroenterol. 22(4):376–380.

8. Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., Shepard, K. V. 1995. „Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS“. Journal of Pain and Symptom Management 10(2):89–97.

9. Maida, V. „The synthetic cannabinoid Nabilone improves pain and symptom management in cancer patients“. Text představen v prosinci 2006 na sympoziu o rakovině prsu v San Antoniu.

10. Nelson, K., Walsh, D., Deeter, P., Sheehan, F. 1994. „A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia“. Journal of Palliative Care 10(1):14–18.

11. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., Wadleigh, R. G. 1991 (Nov). „Recent clinical experience with Dronabinol“. Pharmacol Biochem Behav. 40(3):695–700.

12. Mae Lynn Reyes-Rodríguez, Ph.D., Ann Von Holle, M.S., Teresa Frances Ulman, Ph.D., Laura M. Thornton, Ph.D., Kelly L. Klump, Ph.D., Harry Brandt, M.D., Steve Crawford, M.D., Manfred M. Fichter, M.D., Katherine A. Halmi, M.D., Thomas Huber, M.D., Craig Johnson, Ph.D., Ian Jones, M.D., Allan S. Kaplan, M.D., FRCP(C), James E. Mitchell, M.D., Michael Strober, Ph.D., Janet Treasure, M.D., D. Blake Woodside, M.D., Wade H. Berrettini, M.D., Walter H. Kaye, M.D., Cynthia M. Bulik, Ph.D. July 2011. „Posttraumatic stress disorder in anorexia nervosa“. Psychosomatic Medicine 73(6):491–497.

13. Tracey D. Wade, Ph.D., Marika Tiggemann, Ph.D., Cynthia M. Bulik, Ph.D., Christopher G. Fairburn, F.Med.Sci, Naomi R. Wray, Ph.D., Nicholas G. Martin, Ph.D. 2008. „Shared temperament risk factors for anorexia nervosa: A twin study“. Psychosomatic Medicine 70:239–244.

14. Olga Pollatos, M.D., Ph.D., Beate M. Herbert, Ph.D., Rainer Schandry, Ph.D., Klaus Gramann, Ph.D. 2008.„Impaired central processing of emotional faces in anorexia nervosa“. Psychosomatic Medicine 70:701–708.

15. Tirapelli, C. R., de Andrade, C. R., Cassano, A. O., De Souza, F. A., Ambrosio, S. R., da Costa, F. B., de Oliveira, A. M. 2007 (Mar 1). „Antispasmodic and relaxant effects of the hidroalcoholic extract of Pimpinella anisum (Apiaceae) on rat anococcygeus smooth muscle“. J Ethnopharmacol. 110(1):23–29.

16. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

17. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

18. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

19. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Viz pozn. 17.

20. Birdane, F. M., Cemek, M., Birdane, Y. O., Gülçin, I., Büyükokurolu, M. E. 2007 (Jan 28). „Beneficial effects of Foeniculum vulgare on ethanol-induced acute gastric mucosal injury in rats“. World J Gastroenterol. 13(4):607–611.

21. Ozbek, H., Ura, S., Dülger, H., Bayram, I., Tuncer, I., Oztürk, G., Oztürk, A. 2003 (Apr). „Hepatoprotective effect of Foeniculum vulgare essential oil“. Fitoterapia 74(3):317–319.

22. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

23. Blesching, Uwe, Ph.D. 2009. Spicy Healing: A Global Guide to Growing and Using Spices for Food and Medicine (Berkeley, Kalifornie: Logos Publishing, 2. vydání).

24. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

25. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

26. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Viz pozn. 17.

Bakteriální infekce

Kapavka

1. Centers for Disease Control and Prevention. Stránka naposledy aktualizována 2. září 2010. „Sexually Transmitted Diseases (STDs). Antibiotic-Resistant Gonorrhea. Only one remaining class of antibiotics is recommended for the treatment of gonorrhea“. www.cdc.gov/std/gonorrhea/arg/default.htm

2. Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, M. Mukhlesur Rahman. 2008. „Antibacterial cannabinoids from Cannabis sativa: A structure−activity study“. J. Nat. Prod. 71(8):1427–1430.

3. Touw, Mia. 1981 (Jan-Mar). „The religious and medicinal uses of cannabis in China, India and Tibet“. Journal of Psychoactive Drugs 13(1).

4. Sam’l O. L. Potter, M.A., M.D., MRCP (Lond.) 1892. A Compend of Materia Medica and Therapeutics and Prescription Writing; with especial references to the physiological actions of drugs (Philadelphia: U.S. Pharmacopeia, 5. vydání. P. Blakiston, Son & Co.), s. 124.

5. V roce 1935 propagováno v prodejním a cenovém katalogu, CANNABINE Comp. Mfg. Společnost Chicago Pharmacal Co., 5547 E. Ravenswood Ave., Chicago, USA.

6. Takeda, S., Misawa, K., Yamamoto, I., Watanabe, K. 2008 (Sep). „Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis“. Drug Metab Dispos. 36(9):1917–1921.

7. Blesching, Uwe, Ph.D. 2009. Spicy Healing: A Global Guide to Growing and Using Spices for Food and Medicine (Berkeley, Kalifornie: Logos Publishing, 2. vydání).

8. Koutsky, L. 1997. „Epidemiology of genital human papillomavirus infection“. American Journal of Medicine 102(5A):3–8.

9. Bergsson, G., Steingrímsson, O., Thormar, H. 1999 (Nov). „In vitro susceptibilities of Neisseria gonorrhoeae to fatty acids and monoglycerides“. Antimicrob Agents Chemother. 43(11):2790–2792.

10. Bergsson, G., Arnfinnsson, J., Steingrímsson, O., Thormar, H. 2001 (Oct). „Killing of Gram-positive cocci by fatty acids and monoglycerides“. APMIS. 109(10):670–678.

11. Bergsson, G., Arnfinnsson, J., Steingrímsson, O., Thormar, H. 2001 (Nov). „In vitro killing of Candida albicans by fatty acids and monoglycerides“. Antimicrob Agents Chemother. 45(11):3209–3212.

12. Bergsson, G., Arnfinnsson, J., Karlsson, S. M., Steingrímsson, O., Thormar, H. 1998 (Sep). „In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides“. Antimicrob Agents Chemother. 42(9):2290–2294.

Meticilin-rezistentní zlatý stafylokok (MRSA)

1. Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, M. Mukhlesur Rahman. 2008. „Antibacterial cannabinoids from Cannabis sativa: A structure−activity study“. J. Nat. Prod. 71(8):1427–1430.

2. Cutler, R. R., Wilson, P. 2004. „Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus“. Br J Biomed Sci. 61(2):71–74.

3. Tsao, S. M., Hsu, C. C., Yin, M. C. 2003 (Dec). „Garlic extract and two diallyl sulphides inhibit methicillin-resistant Staphylococcus aureus infection in BALB/cA mice“. J Antimicrob Chemother. 52(6):974–980.

4. Edwards-Jones, V., Buck, R., Shawcross, S. G., Dawson, M. M., Dunn, K. 2004 (Dec). „The effect of essential oils on methicillin-resistant Staphylococcus aureus using a dressing model“. Burns 30(8):772–777.

5. Imai, H., Osawa, K., Yasuda, H., Hamashima, H., Arai, T., Sasatsu, M. 2001. „Inhibition by the essential oils of peppermint and spearmint of the growth of pathogenic bacteria“. Microbios. 106 Suppl 1:31–39.

6. Hada, T., Furuse, S., Matsumoto, Y., Hamashima, H., Masuda, K., Shiojima, K., Arai, T., Sasatsu, M. 2001. „Comparison of the effects in vitro of tea tree oil and plaunotol on methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus“. Microbios. 106 Suppl 2:133–141.

7. Bowling, F. L., Salgami, E. V., Boulton, A. J. 2007 (Feb). „Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers“. Care 30(2):370–371.

Virové infekce

1. Janice K. Kiecolt-Glaser, Ph.D., Lynanne McGuire, Ph.D., Theodore F. Robles, BS, Ronald Glaser, Ph.D. 2002. „Psychoneuroimmunology and psychosomatic medicine: Back to the future“. Psychosomatic Medicine 64:15–28.

Kiecolt-Glaser, J. K., Loving, T. J., Stowell, J. R., Malarkey, W. B., Lemeshow, S., Dickinson, S. L., Glaser, R. 2005 (Dec). „Hostile marital interactions, proinflammatory cytokine production, and wound healing“. Arch Gen Psychiatry 62(12):1377–1384.

2. Tabassum, A. Khan, Pratima A. Tatke, Satish Y. Gabhe. 2006 (Nov 12-16). „Evaluation of aqueous extract of babool pods for in vitro anti-HIV activity“. Int Cong Drug Therapy HIV 8: Abstract No. P399.

3. Chiang, L. C., Ng, L. T., Cheng, P. W., Chiang, W., Lin, C. C. 2005 (Oct). „Antiviral activities of extracts and selected pure constituents of Ocimum basilicum“. Clin Exp Pharmacol Physiol. 32(10):811–816.

4. Bourne, K. Z., Bourne, N., Reising, S. F., Stanberry, L. R. 1999 (Jul). „Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against Herpes simplex virus type 2“. Antiviral Res. 42(3):219–226.

5. Kurokawa, M., Hozumi, T., Basnet, P., Nakano, M., Kadota, S., Namba, T., Kawana, T., Shiraki, K. 1998 (Feb). „Purification and characterization of eugenine as an anti-herpes virus compound from Geum japonicum and Syzygium aromaticum“. J Pharmacol Exp Ther. 284(2):728–735.

6. Chaieb, K., Hajlaoui, H., Zmantar, T., Kahla-Nakbi, A. B., Rouabhia, M., Mahdouani, K., Bakhrouf, A. 2007 (Jun). „The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): a short review“. Phytother Res. 21(6):501–506.

7. Isaacs, C. E., Kim, K. S., Thormar, H. 1994 (Jun 6). „Inactivation of enveloped viruses in human bodily fluids by purified lipids“. Ann N Y Acad Sci. 724:457–464.

8. Esquenazi, D., Wigg, M.D., Miranda, M. M., Rodrigues, H. M., Tostes, J. B., Rozental, S., da Silva, A. J., Alviano, C. S. 2002 (Dec). „Antimicrobial and antiviral activities of polyphenolics from Cocos nucifera Linn. (Palmae) husk fiber extract“. Res Microbiol. 153(10):647–652.

9. Kutluay, S. B., Doroghazi, J., Roemer, M. E., Triezenberg, S. J. 2008 (Apr 10). „Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity“. Virology 373(2):239–247.

Nachlazení a chřipka

1. Světová zdravotnická organizace (WHO). Mediální centrum. „Influenza (seasonal)“. Zpráva č. 211. Březen 2014. www.who.int/mediacentre/factsheets/fs211/en/

2. Louis Sanford Goodman, Alfred Gilman, Laurence L. Brunton, John S. Lazo. 2001. Goodman & Gilman’s The Pharmacological Basis of Therapeutics (New York: McGraw-Hill, 10. vydání).

3. Toby L. Litovitz, M.D., Wendy Klein-Schwartz, Pharm.D., MPH, K. Sophia Dyer, M.D., Michael Shannon, M.D., MPH, Shannon Lee, BSPharm, CSPI, Meggan Power. 1998. Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System 1997 (Elsevier Inc.).

4. Internetová stránka amerických Center pro kontrolu nemocí (CDC) uvádí k možným vedlejším účinkům antivirotik následující: „S užíváním antivirotik proti chřipce jsou spojeny některé vedlejší účinky včetně nevolnosti, zvracení, závratí, rýmy nebo ucpaného nosu, kašle, průjmu, bolesti hlavy a vlivu na chování.“ Dostupné 16. dubna 2015. www.cdc.gov/flu/antivirals/whatyoushould.htm

5. Nourjah, P., Ahmad, S. R., Karwoski, C., Willy, M. 2006 (Jun). „Estimates of acetaminophen (Paracetamol)-associated overdoses in the United States“. Pharmacoepidemiol Drug Saf. 15(6):398–405.

6. Wolfe, Sidney M., M.D. 1989. „Antibiotics“. Public Citizen’s Health Research Group. Washington, D.C. Health Letter 5(7):1–5.

7. Je poměrně málo známým faktem, že ke 12. dubnu 2005 bylo odškodněno 11 302 případů újmy způsobené thimerosalem (4 689 případů autismu a 6 613 neautistických případů) a kompenzace vyplacené 1 910 rodinám činily celkově více než 1,5 miliardy dolarů. V současnosti program pokrývá následující vakcíny: proti záškrtu, tetanu, černému kašli (DTP, DTaP, DT, TT nebo Td), spalničkám, příušnicím, zarděnkám (MMR nebo jakékoli složky), dětské obrně (OPV nebo IPV), hepatitidě typu B, hepatitidě typu A, bakterii Haemophilus influenzae typu b (Hib), planým neštovicím (varicella) a rotaviru a kombinovanou vakcínu proti pneumokokovým infekcím. K 1. červenci 2005 program VICP (Vaccine Injury Compensation Program) pokrýval také trivalentní vakcíny proti chřipce. VAERS, P.O. Box 1100, Rockville, Maryland 20849-1100; telefon: 1‑800‑822‑7967.

8. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (July 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

9. Sheldon Cohen, Ph.D., William J. Doyle, Ph.D., Ronald B. Turner, M.D., Cuneyt M. Alper, M.D., David P. Skoner, M.D. 2003. Emotional Style and Susceptibility to the Common Cold. Katedra psychologie, Carnegie Mellon University, Pittsburgh (Cohen); oddělení otolaryngologie (Doyle, Alper) a pediatrie (Skoner) Dětské nemocnice v Pittsburghu a lékařská fakulta Pittsburské univerzity, Pittsburgh, Pennsylvánie; katedra pediatrie Medical University of South Carolina v Charlestonu (Turner; nyní v Centru zdravotních věd Virginské univerzity v Charlottesville). Psychosomatic Medicine 65:652–657.

10. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

11. Boskabady, M. H., Ramazani-Assari, M. 2001 (Jan). „Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s)“. J Ethnopharmacol. 74(1):83–88.

12. Isaacs, C. E., Kim, K. S., Thormar, H. 1994 (Jun 6). „Inactivation of enveloped viruses in human bodily fluids by purified lipids“. Ann N Y Acad Sci. 724:457–464.

13. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

14. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

15. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Viz pozn. 13.

16. Ivanova, D., Gerova, D., Chervenkov, T., Yankova, T. 2005 (Jan 4). „Polyphenols and antioxidant capacity of Bulgarian medicinal plants“. J Ethnopharmacol. 96(1-2):145–150.

Kašel

1. Gordon, R., Gordon, R. J., Sofia, D. 1976 (Feb). „Antitussive activity of some naturally occurring cannabinoids in anesthetized cats“. Eur J Pharmacol. 35(2):309–313.

2. United States Patent Application 20060013777. Kind Code A1. Piomelli; Daniele. 19. ledna 2006. Zmocněnec: Regenti Kalifornské univerzity. Podáno 12. září 2005.

3. Tan, W. C., Lo, C., Jong, A., Xing, L., Fitzgerald, M. J., Vollmer, W. M., Buist, S. A., Sin, D. D. 2009 (Apr 14). „Marijuana and chronic obstructive lung disease: A population-based study“. CMAJ 180(8):814–820.

4. United States Patent Application 20060013777; viz pozn. 2.

5. Jeanette M. Tetrault, M.D.; Kristina Crothers, M.D.; Brent A. Moore, Ph.D.; Reena Mehra, M.D., M.S.; John Concato, M.D., M.S., MPH; David A. Fiellin, M.D. 2007. „Effects of marijuana smoking on pulmonary function and respiratory complications. A systematic review“. Arch Intern Med. 167(3):221–228.

Encefalitida

1. Solbrig, M. V., Fan, Y., Hazelton, P. 2013 (Nov 6). „Prospects for cannabinoid therapies in viral encephalitis“. Brain Res. 1537:273–282.

Hepatitida

1. Venkatesh, L. Hegde, Shweta Hegde, Benjamin F. Cravatt, Lorne J. Hofseth, Mitzi Nagarkatti, Prakash S. Nagarkatti. 2008 (Jul). „Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory T cells“. Molecular Pharmacology 74(1):20–33.

2. Costiniuk, C. T., Mills, E., Cooper, C. L. 2008 (Apr). „Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus“. Can J Gastroenterol. 22(4):376–380.

3. Diana L. Sylvestre, Barry J. Clements, Yvonne Malibu. 2006 (Oct). „Cannabis use improves retention and virological outcomes in patients treated for hepatitis C“. Eur J Gastroenterol Hepatol. 18(10):1057–1063.

4. Chiang, L. C., Ng, L. T., Cheng, P. W., Chiang, W., Lin, C. C. 2005 (Oct). „Antiviral activities of extracts and selected pure constituents of Ocimum basilicum“. Clin Exp Pharmacol Physiol. 32(10):811–816.

5. Chaieb, K., Hajlaoui, H., Zmantar, T., Kahla-Nakbi, A. B., Rouabhia, M., Mahdouani, K., Bakhrouf, A. 2007 (Jun). „The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): A short review“. Phytother Res. 21(6):501–506.

6. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

Herpetické infekce

1. Phan, N. Q., Siepmann, D., Gralow, I., Ständer, S. 2010 (Feb). „Adjuvant topical therapy with a cannabinoid receptor agonist in facial post-herpetic neuralgia“. J Dtsch Dermatol Ges. 8(2):88–91.

2. Medveczky, Maria M., Tracy A. Sherwood, Thomas W. Klein, Herman Friedman, Peter G. Medveczky. 2004. „Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpes viruses in vitro“. BMC Med. 2:34.

3. Blevins, R. Dean, Dumic, Michael P. 1980. „The effect of Delta-9-tetrahydrocannabinol on Herpes simplex virus replication“. J Gen Virol. 49:427–431.

4. Schneck, Jerome M. 1947. „The psychological component in a case of Herpes simplex“. Psychosomatic Medicine 9:62–64.

5. Chiang, L. C., Ng, L. T., Cheng, P. W., Chiang, W., Lin, C. C. 2005 (Oct). „Antiviral activities of extracts and selected pure constituents of Ocimum basilicum“. Clin Exp Pharmacol Physiol. 32(10):811–816.

6. Bourne, K. Z., Bourne, N., Reising, S. F., Stanberry, L. R. 1999 (Jul). „Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against Herpes simplex virus type 2“. Antiviral Res. 42(3):219–226.

7. Kurokawa, M., Hozumi, T., Basnet, P., Nakano, M., Kadota, S., Namba, T., Kawana, T., Shiraki, K. 1998 (Feb). „Purification and characterization of eugenine as an anti-herpes virus compound from Geum japonicum and

Syzygium aromaticum“. J Pharmacol Exp Ther. 284(2):728–735.

8. Chaieb, K., Hajlaoui, H., Zmantar, T., Kahla-Nakbi, A. B., Rouabhia, M., Mahdouani, K., Bakhrouf, A. 2007 (Jun). „The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): A short review“. Phytother Res. 21(6):501–506.

9. Esquenazi, D., Wigg, M.D., Miranda, M. M., Rodrigues, H. M., Tostes, J. B., Rozental, S., da Silva, A. J., Alviano, C. S. 2002 (Dec). „Antimicrobial and antiviral activities of polyphenolics from Cocos nucifera Linn. (Palmae) husk fiber extract“. Res Microbiol. 153(10):647–652.

10. Kutluay, S. B., Doroghazi, J., Roemer, M. E., Triezenberg, S. J. 2008 (Apr 10). „Curcumin inhibits Herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity“. Virology 373(2):239–247.

Aggarwal, B. B., Sundaram, C., Malani, N., Ichikawa, H. 2007. „Curcumin: the Indian solid gold“. Adv Exp Med Biol. 595:1–75.

HIV/AIDS

1. Corless, I. B., Lindgren, T., Holzemer, W., Robinson, L., Moezzi, S., Kirksey, K., Coleman, C., Tsai, Y. F., Sanzero, Eller L., Hamilton, M. J., Sefcik, E. F., Canaval, G. E., Rivero Mendez, M., Kemppainen, J. K., Bunch, E. H., Nicholas, P. K., Nokes, K. M., Dole, P., Reynolds, N. 2009 (May). „Marijuana effectiveness as an HIV self-care strategy“. Clin Nurs Res. 18(2):172–193.

3. Isaacs, C. E., Kim, K. S., Thormar, H. 1994 (Jun 6). „Inactivation of enveloped viruses in human bodily fluids by purified lipids“. Ann N Y Acad Sci. 724:457–464.

Rakovina (obecně)

1. Světová zdravotnická organizace (WHO). Únor 2009. Zpráva č. 297. „Cancer“.

2. Dr. John W. Gofman, emeritní profesor molekulární a buněčné biologie Kalifornské univerzity v Berkeley, prokázal, že působení ionizujícího záření během života, na němž se podílejí také lékařská rentgenová vyšetření, ve Spojených státech zodpovídá za více než 50 % všech případů rakoviny, více než 50 % případů koronárních srdečních onemocnění a zhruba 75 % problémů s karcinomem prsu. Viz následující:

Gofman, John W. Radiation from Medical Procedures in the Pathogenesis of Cancer and Ischemic Heart Disease: Dose Response Studies with Physicians per 100,000 Population (San Francisco: Committee for Nuclear Responsibility, 1999).

Gofman, John W. Preventing Breast Cancer: The Story of a Major, Proven, Preventable Cause of this Disease (San Francisco: Committee for Nuclear Responsibility, 2. vydání, únor 1996).

3. Cohn, Victor. „Cancer curb is studied: Doctors eye drug found in marijuana“. Washington Post, Aug 18, 1974.

4. Pan, H., Mukhopadhyay, P., Rajesh, M., Patel, V., Mukhopadhyay, B., Gao, B., Haskó, G., Pacher, P. 2009 (Mar). „Cannabidiol attenuates cisplatininduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death“. J Pharmacol Exp Ther. 328(3):708–714.

5. Grossarth-Maticek, R., Siegrist, J., Vetter, H. 1982. „Interpersonal repression as a predictor of cancer“. Soc Sci Med. 16(4):493–498.

6. Shaffer, J. W., Graves, P. L., Swank, R. T., Pearson, T. A. 1987 (Oct). „Clustering of personality traits in youth and the subsequent development of cancer among physicians“. J Behav Med. 10(5):441–447.

7. LeShan, Lawrence, Ph.D. Cancer as a Turning Point: A Handbook for People with Cancer, Their Families, and Health Professionals (A Plume Book, 1989).

8. Fisher, Seymour, Ph.D., Cleveland, Sidney E., Ph.D. „Relationship of body image to site of cancer“. 1956. Psychosomatic Medicine 18:304–309.

9. Holland, Jimmie C., M.D. 2002. „History of psycho-oncology: Overcoming attitudinal and conceptual barriers“. Psychosomatic Medicine 64:206–221.

10. Bacon, C., M.D., Rennekerr, R., M.D., Cutler, Max, M.D. 1952 (Nov 1). „A psychosomatic survey of cancer of the breast“. Psychosomatic Medicine 14(6):453–460.

11. Everson, S. A., Goldberg, D. E., Kaplan, G. A., Cohen, R. D., Pukkala, E., Tuomilehto, J., Salonen, J. T. 1996 (Mar-Apr). „Hopelessness and risk of mortality and incidence of myocardial infarction and cancer“. Psychosomatic Medicine 58(2): 113–121.

12. Meena, P. D., Kaushik, P., Shukla, S., Soni, A. K., Kumar, M., Kumar, A. 2006 (Oct-Dec). „Anticancer and antimutagenic properties of Acacia nilotica (Linn.) on 7,12-dimethylbenz(a)anthracene-induced skin papillomagenesis in Swiss albino mice“. Asian Pac J Cancer Prev. 7(4):627–632.

13. Dasgupta, T., Rao, A. R., Yadava, P. K. 2004 (Feb). „Chemomodulatory efficacy of basil leaf (Ocimum basilicum) on drug metabolizing and antioxidant enzymes, and on carcinogen-induced skin and forestomach papilloma-genesis“. Phytomedicine 11(2-3):139–151.

14. Lee, E. J., Jang, H. D. 2004. „Antioxidant activity and protective effect on DNA strand scission of rooibos tea (Aspalathus linearis)“. Biofactors 21(1-4):285–292.

15. Marnewick, J., Joubert, E., Joseph, S., Swanevelder, S., Swart, P., Gelderblom, W. 2005 (Jun 28). „Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas“. Cancer Lett. 224(2):193–202.

16. Kamaleeswari, M., Nalini, N. 2006 (Aug). „Dose-response efficacy of caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis“. J Pharm Pharmacol. 58(8):1121–1130.

17. Mazaki, M., Kataoka, K., Kinouchi, T., Vinitketkumnuen, U., Yamada, M., Nohmi, T., Kuwahara, T., Akimoto, S., Ohnishi, Y. 2006 (Feb). „Inhibitory effects of caraway (Carum carvi L.) and its component on N-methyl-N’-nitro-N-nitrosoguanidine-induced mutagenicity“. J Med Invest. 53(1-2):123–133.

18. Sengupta, A., Ghosh, S., Bhattacharjee, S. 2005 (Apr-Jun). „Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon“. Asian Pac J Cancer Prev. 6(2):118–122.

19. Sánchez, A. M., Sánchez, M. G., Malagarie-Cazenave, S., Olea, N., Díaz-Laviada, I. 2006 (Jan). „Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin“. Apoptosis 11(1):89–99.

20. Beltran, J., Ghosh, A. K., Basu, S. 2007 (Mar 1). „Immunotherapy of tumors with neuroimmune ligand capsaicin“. J Immunol. 178(5):3260–3264.

21. Banerjee, S., Panda, C. K., Das, S. 2006 (Aug). „Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer“. Carcinogenesis 27(8):1645–1654.

22. Banerjee, S., Das, S. 2005 (Jul-Sep). „Anticarcinogenic effects of an aqueous infusion of cloves on skin carcinogenesis“. Asian Pac J Cancer Prev. 6(3):304–308.

23. Ramljak, D., Romanczyk, L. J., Metheny-Barlow, L. J., Thompson, N., Knezevic, V., Galperin, M., Ramesh, A., Dickson, R. B. 2005 (Apr). „Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells“. Mol Cancer Ther. 4(4):537–546.

24. Howard, E. W., Ling, M. T., Chua, C. W., Cheung, H. W., Wang, X., Wong, Y. C. 2007 (Mar 15). „Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer“. Clin Cancer Res. 13(6):1847–1856.

25. Herman-Antosiewicz, A., Powolny, A. A., Singh, S. V. 2007 (Sep). „Molecular targets of cancer chemoprevention by garlic-derived organosulfides“. Acta Pharmacol Sin. 28(9):1355–1364.

26. Lu, H. F., Yang, J. S., Lin, Y. T., Tan, T. W., Ip, S. W., Li, Y. C., Tsou, M. F., Chung, J. G. 2007 (Mar-Apr). „Diallyl disulfide-induced signal transducer and activator of transcription 1 expression in human colon cancer colo 205 cells using differential display RT-PCRy“. Cancer Genomics Proteomics 4(2):93–98.

27. Lee, H. S., Seo, E. Y., Kang, N. E., Kim, W. K. 2008 (May). „[6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells“. J Nutr Biochem. 19(5):313-319.

28. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

29. Shishodia, S., Sethi, G., Ahn, K. S., Aggarwal, B. B. 2007 (Jun 30). „Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products“. Biochem Pharmacol. 74(1):118–130.

30. Kaseb, A. O., Chinnakannu, K., Chen, D., Sivanandam, A., Tejwani, S., Menon, M., Dou, Q. P., Reddy, G. P. 2007 (Aug 15). „Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer“. Cancer Res. 67(16):7782–7788.

31. Ait Mbarek, L., Ait Mouse, H., Elabbadi, N., Bensalah, M., Gamouh, A., Aboufatima, R., Benharref, A., Chait, A., Kamal, M., Dalal, A., Zyad, A. 2007 (Jun). „Anti-tumor properties of blackseed (Nigella sativa L.) extracts“. Braz J Med Biol Res. 40(6):839–847.

32. Norwood, A. A., Tucci, M., Benghuzzi, H. 2007. „A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells“. Biomed Sci Instrum. 43:272–277.

33. Goun, E., Cunningham, G., Solodnikov, S., Krasnykch, O., Miles, H. 2002 (Dec). „Antithrombin activity of some constituents from Origanum vulgare“. Fitoterapia 73(7-8):692–694.

34. Peng, C. H., Su, J. D., Chyau, C. C., Sung, T. Y., Ho, S. S., Peng, C. C., Peng, R. Y. 2007 (Sep). „Supercritical fluid extracts of rosemary leaves exhibit potent anti-inflammation and anti-tumor effects“. Biosci Biotechnol Biochem. 71(9):2223–2232.

35. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Aggarwal, B. B., Kumar, A., Bharti, A. C. 2003 (Jan-Feb). „Anticancer potential of curcumin: Preclinical and clinical studies“. Anticancer Research 23(1A):363–398.

36. Lee, E. J., Jang, H. D. 2004. „Antioxidant activity and protective effect on DNA strand scission of rooibos tea (Aspalathus linearis)“. Biofactors 21(1-4):285–292.

37. Marnewick, J., Joubert, E., Joseph, S., Swanevelder, S., Swart, P., Gelderblom, W. 2005 (Jun 28). „Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas“. Cancer Lett. 224(2):193–202.

38. Mitani, H., Ryu, A., Suzuki, T., Yamashita, M., Arakane, K., Koide, C. 2007 (Apr-Jun). „Topical application of plant extracts containing xanthine derivatives can prevent UV-induced wrinkle formation in hairless mice“. Photodermatol Photoimmunol Photomed. 23(2-3):86–94.

39. Singh, S. P., Abraham, S. K., Kesavan, P. C. 1996 (Jul). „Radioprotection of mice following garlic pretreatment“. Br J Cancer Suppl. 27:S102–104.

40. Cemek, M., Enginar, H., Karaca, T., Unak, P. 2006 (Nov-Dec). „In vivo radioprotective effects of Nigella sativa L. oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats“. Photochem Photobiol. 82(6):1691–1696.

41. Sharma, M., Kumar, M. 2007 (Mar). „Radioprotection of Swiss albino mice by Myristica fragrans houtt“. J Radiat Res (Tokyo) 48(2):135–141.

42. Soyal, D., Jindal, A., Singh, I., Goyal, P. K. 2007 (Oct). „Modulation of radiation-induced biochemical alterations in mice by rosemary (Rosmarinus officinalis) extract“. Phytomedicine 14(10):701–705.

43. Horváth, Béla, Partha Mukhopadhyay, Malek Kechrid, Vivek Patel, Gali Tanchian, David A. Wink, Jürg Gertsch, Pál Pacher. 2012 (April 15). „β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner“. Free Radical Biology and Medicine 52(8):1325–1333.

Rakovina kostí

1. Lozano-Ondoua, A. N., Wright, C., Vardanyan, A., King, T., Largent-Milnes, T. M., Nelson, M., Jimenez-Andrade, J. M., Mantyh, P. W., Vanderah, T. W. 2010 (Apr 24). „A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss“. Life Sci. 86(17-18):646–653.

2. Khasabova, I. A., Khasabov, S. G., Harding-Rose, C., Coicou, L. G., Seybold, B. A., Lindberg, A. E., Steevens, C. D., Simone, D. A., Seybold, V. S. 2008 (Oct 29). „A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain“. J Neurosci. 28(44):11141–11152.

3. Idris, A. I. 2008 (Dec). „Role of cannabinoid receptors in bone disorders: Alternatives for treatment“. Drug News Perspect. 21(10):533–540.

4. Jestliže hrudní kost bereme jako útvar složený ze tří kostí, člověk má celkem 208 kostí.

Rakovina mozku

1. Vyšetření metodou výpočetní tomografie se neobejde bez poměrně vysoké dávky karcinogenního ionizujícího záření.

2. Surawicz, Tanya S., Faith Davis, Sally Freels, Edward R. Laws, Herman R. Menck. 1998. „Brain tumor survival: Results from the National Cancer Data Base“. Journal of Neuro-Oncology 40(2):151–160.

3. Sanchez, Cristina, Maria L. de Ceballos, Teresa Gomez del Pulgar, Daniel Rueda, Cesar Corbacho, Guillermo Velasco, Ismael Galve-Roperh, John W. Huffman, Santiago Ramon y Cajal, Manuel Guzman. 2001 (Aug 1).„Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor“. Cancer Research 61:5784–5789.

4. Massi, Paola, Angelo Vaccani, Stefania Ceruti, Arianna Colombo, Maria P. Abbracchio, Daniela Parolaro. 2004 (March). „Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines“. JPET 308(3):838–845.

5. Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., Parolaro, D. 2006 (Sep). „The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells“. Cell Mol Life Sci. 63(17):2057–2066.

6. Blázquez, Cristina, Luis González-Feria, Luis Álvarez, Amador Haro, M. Llanos Casanova, Manuel Guzmán. 2004 (Aug 15). „Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas“. Cancer Res. 64:5617.

7. Guzmán, M., Duarte, M. J., Blazquez, C., Ravina, J., Rosa, M. C., Galve-Roperh, I., Sanchez, C., Velasco, G., Gonzalez-Feria, L. 2006. „A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme“. Br J Cancer 95(2):197–203.

8. Galanti, Gil, Tamar Fisher, Iris Kventsel, Jacob Shoham, Ruth Gallily, Raphael Mechoulam, Gad Lavie, Ninette Amariglio, Gideon Rechavi, Amos Toren. 2008. „Δ⁹-Tetrahydrocannabinol inhibits cell cycle progression by down-regulation of E2F1 in human glioblastoma multiforme cells“. Acta Oncologica 47:1062.

9. Blázquez, C., Carracedo, A., Salazar, M., Lorente, M., Egia, A., González-Feria, L., Haro, A., Velasco, G., Guzmán, M. 2008 (Jan). „Downregulation of tissue inhibitor of metalloproteinases-1 in gliomas: A new marker of cannabinoid antitumoral activity?“ Neuropharmacology 54(1):235–243.

10. Marcu, J. P., Christian, R. T., Lau, D., Zielinski, A. J., Horowitz, M. P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D. H., Yount, G. L., Desprez, P. Y., McAllister, S. D. 2010 (Jan). „Cannabidiol enhances the inhibitory effects of {Delta}9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival“. Mol Cancer Ther 6.

Rakovina prsu

1. Světová zdravotnická organizace (WHO). Únor 2009. Zpráva č. 297. „Cancer“.

2. U.S. National Institutes of Health. National Cancer Institute. 23. července 2010. „Breast Cancer Prevention. Factors Associated with Increased Risk of Breast Cancer. Ionizing radiation“. www.cancer.gov/cancertopics/pdq/prevention/breast/healthprofessional#Section_178

3. Gofman, John W., M.D., Ph.D. Preventing Breast Cancer: The Story of a Major, Proven, Preventable Cause of This Disease (San Francisco: Committee for Nuclear Responsibility, 2. vydání, 1996).

4. Collaborative Group on Hormonal Factors in Breast Cancer. 2002. „Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease“. Lancet 360(9328):187–195.

5. De Petrocellis, Luciano, Dominique Melck, Antonella Palmisano, Tiziana Bisogno, Chiara Laezza, Maurizio Bifulco, Vincenzo Di Marzo. 1998 (Jul 7). „The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation“. PNAS 95(14):8375–8380.

6. Melck, Dominique, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, Chiara Laezza, Maurizio Bifulco, Vincenzo Di Marzo. 2000. „Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation“. Endocrinology 141(1):118–126.

7. Ligresti, Alessia, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano De Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco, Vincenzo Di Marzo. 2006 (Sep). „Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma“. JPET 318(3):1375–1387.

8. Caffarel, María M., David Sarrió, José Palacios, Manuel Guzmán, Cristina Sánchez. 2006 (Jul 1). „Δ⁹‑Tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation“. Cancer Res. 66:6615.

9. McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., Desprez, P. Y. 2007 (Nov). „Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells“. Mol Cancer Ther. 6(11):2921–2927.

10. Caffarel, M. M., Moreno-Bueno, G., Cerutti, C., Palacios, J., Guzmán, M., Mechta-Grigoriou, F., Sanchez, C. 2008 (Aug 28). „JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells“. Oncogene 27(37):5033–5044.

11. Bacon, C., M.D., Rennekerr, R., M.D., Cutler, Max, M.D. 1952 (Nov 1). „A psychosomatic survey of cancer of the breast“. Psychosomatic Medicine 14(6):453–460.

12. Immunoglobulin A (IgA): protilátky, které imunitní systém organismu tvoří v reakci na ohrožení, jakým je rakovina.

13. Pettingale, K. W., Greer, S., Tee, D. E. H. 1977. „Serum IgA and emotional expression in breast cancer patients“. J Psychosom Med 21:395–399.

14. Weihs, Karen L., M.D., Timothy M. Enright, Ph.D., Samuel J. Simmens, Ph.D. 2008 (Jan 1). „Close relationships and emotional processing predict decreased mortality in women with breast cancer: Preliminary evidence“. Psychosomatic Medicine 70(1):117–124.

15. Renneker, Richard E., M.D., Robert Cutler, M.D., Jerome Hora, M.D., Catherine Bacon, M.D., Garnet Bradley, M.D., John Kearney, M.D., Max Cutler, M.D. 1963. „Psychoanalytical explorations of emotional correlates of cancer of the breast“. Psychosomatic Medicine 25:106–123.

16. White, Victoria M., Ph.D., Dallas R. English, Ph.D., Hamish Coates, Ph.D., Magdalena Lagerlund, Ph.D., Ron Borland, Ph.D., Graham G. Giles, Ph.D. 2007. „Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study“. Psychosomatic Medicine 69:667–674.

17. Chua, S., Arulkumaran, S., Lim, I., Selamat, N., Ratnam, S. S. 1994. „Influence of breastfeeding and nipple stimulation on postpartum uterine activity“. Br J Obstet Gynaecol. 101:804–805.

18. Newcomb, P. A., Storer, B. E., Longnecker, M. P. et al. 1994. „Lactation and a reduced risk of premenopausal breast cancer“. N Engl J Med. 330:81–87.

Collaborative Group on Hormonal Factors in Breast Cancer. 2002. „Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease“. Lancet 360(9328):187–195.

Tryggvadóttir, L., Tulinius, H., Eyfjord, J. E., Sigurvinsson, T. 2001. „Breastfeeding and reduced risk of breast cancer in an Icelandic cohort study“. Am J Epidemiol. 154:37–42.

19. American Society of Plastic Surgeons (ASPS). 2000/2007/2008 „National Plastic Surgery Statistics“. Dostupné 16. dubna 2015. www.plasticsurgery.org/Documents/news-resources/statistics/2008-statistics/2008-top-5-cosmetic-surgery-procedures-graph.pdf

20. American Cancer Society. 2010. „Cancer Facts and Figures 2010“. Atlanta, Georgia. Dostupné 16. dubna 2015. www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf

21. Kassi, E., Papoutsi, Z., Fokialakis, N., Messari, I., Mitakou, S., Moutsatsou, P. 2004 (Nov 17). „Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties“. J Agric Food Chem. 52(23):6956–6961.

22. Ramljak, D., Romanczyk, L. J., Metheny-Barlow, L. J., Thompson, N., Knezevic, V., Galperin, M., Ramesh, A., Dickson, R. B. 2005 (Apr). „Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells“. Mol Cancer Ther. 4(4):537–546.

23. Lee, H. S., Seo, E. Y., Kang, N. E., Kim, W. K. 2008 (May). „[6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells“. J Nutr Biochem. 19(5):313-319.

24. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

25. Shishodia, S., Sethi, G., Ahn, K. S., Aggarwal, B. B. 2007 (Jun 30). „Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products“. Biochem Pharmacol. 74(1):118–130.

Rakovina zaviněná konopím?

1. Trabert, B., Sigurdson, A. J., Sweeney, A. M., Strom, S. S., McGlynn, K. A. 2011 (Feb 15). „Marijuana use and testicular germ cell tumors“. Cancer 117(4):848–853.

2. Singh, R., Sandhu, J., Kaur, B., Juren, T., Steward, W. P., Segerbäck, D., Farmer, P. B. 2009 (Jun). „Evaluation of the DNA-damaging potential of cannabis cigarette smoke by the determination of acetaldehyde-derived N2-ethyl-2’-deoxyguanosine adducts“. Chem Res Toxicol. 22(6):1181–1188.

3. Berthiller, J., Straif, K., Boniol, M., Voirin, N., Benhaïm-Luzon, V., Ayoub, W. B., Dari, I., Laouamri, S., Hamdi-Cherif, M., Bartal, M., Ayed, F. B., Sasco, A. J. 2008 (Dec). „Cannabis smoking and risk of lung cancer in men: A pooled analysis of three studies in Maghreb“. J Thorac Oncol. 3(12): 1398–1403.

4. Aldington, S., Harwood, M., Cox, B., Weatherall, M., Beckert, L., Hansell, A., Pritchard, A., Robinson, G., Beasley, R. 2008 (Feb). „Cannabis use and risk of lung cancer: A case-control study“. Eur Respir J. 31(2):280–286.

5. Hashibe, M., Morgenstern, H., Cui, Y., Tashkin, D. P., Zhang, Z. F., Cozen, W., Mack, T. M., Greenland, S. 2006 (Oct). „Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-control study“. Cancer Epidemiol Biomarkers Prev. 15(10):1829–1834.

6. Hashibe, M., Straif, K., Tashkin, D. P., Morgenstern, H., Greenland, S., Zhang, Z. F. 2005 (Apr). „Epidemiologic review of marijuana use and cancer risk“. Alcohol 35(3):265–275.

Noční pocení vyvolané rakovinou

1. Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Ogata, A., Fujioka, M., Harada, K., Mishima, S., Orito, K., Egashira, N., Iwasaki, K., Fujiwara, M. 2007 (Mar 27). „Δ⁹-tetrahydrocannabinol (Δ⁹-THC) prevents cerebral infarction via hypothalamic-independent hypothermia“. Life Sci. 80(16):1466–1471.

2. Maida, V. 2008 (Jul). „Nabilone for the treatment of paraneoplastic night sweats: A report of four cases“. J Palliat Med. 11(6):929–934.

Rakovina děložního hrdla

1. Sedjo, R. L., Roe, D. J., Abrahamsen, M., Harris, R. B., Craft, N., Baldwin, S., Giuliano, A. R. 2002 (Sep). „Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection“. Cancer Epidemiol Biomarkers Prev. 11(9):876–884.

2. Contassot, E., Tenan, M., Schnüriger, V., Pelte, M. F., Dietrich, P. Y. 2004 (Apr). „Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1“. Gynecol Oncol. 93(1):182–188.

3. Ramer, R., Hinz, B. 2008 (Jan 2). „Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1“. J Natl Cancer Inst. 100(1):59–69.

4. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

Rakovina tlustého střeva (kolorektální karcinom)

1. National Cancer Institute at the National Institutes for Health. „Colon and Rectal Cancer. Estimated new cases and deaths from colon and rectal cancer in the United States in 2010“. www.cancer.gov/cancertopics/types/colon-and-rectal

2. Ruhaak, L. R., Felth, J., Karlsson, P. C., Rafter, J. J., Verpoorte, R., Bohlin, L. 2011. „Evaluation of the cyclooxygenase-inhibiting effects of six major cannabinoids isolated from Cannabis sativa“. Biol Pharm Bull. 34(5):774–778.

3. Patsos, H. A., Hicks, D. J., Dobson, R. R. H., Greenhough, A., Woodman, N., Lane, J. D., Williams, A. C., Paraskeva, C. 2005. „The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: A possible role for cyclooxygenase 2“. Gut 54:1741–1750.

4. Wang, D., Wang, H. Ning, W., Backlund, M. G, Dey, S. K., Dubois, R. N. 2008 (Aug 1). „Loss of cannabinoid receptor 1 accelerates intestinal tumor growth“. Cancer Res. 68(15):6468–6476.

5. Kune, Gabriel A., Susan Kune, Lyndsey F. Watson, Claus Bahne Bahnson. 1991.„Personality as a risk factor in large bowel cancer: Data from the Melbourne Colorectal Cancer Study“. Psychological Medicine 21:29–41.

6. Dasgupta, T., Rao, A. R., Yadava, P. K. 2004 (Feb). „Chemomodulatory efficacy of basil leaf (Ocimum basilicum) on drug metabolizing and antioxidant enzymes, and on carcinogen-induced skin and forestomach papilloma-genesis“. Phytomedicine 11(2-3):139–151.

7. Kamaleeswari, M., Nalini, N. 2006 (Aug). „Dose-response efficacy of caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis“. J Pharm Pharmacol. 58(8):1121–1130.

8. Deeptha, K., Kamaleeswari, M., Sengottuvelan, M., Nalini, N. 2006 (Nov). „Dose-dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine-induced colonic aberrant crypt foci and bacterial enzyme activity in rats“. Invest New Drugs. 24(6):479–488.

9. Sengupta, A., Ghosh, S., Bhattacharjee, S. 2005 (Apr-Jun). „Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon“. Asian Pac J Cancer Prev. 6(2):118–122.

10. Nalini, N., Manju, V., Menon, V. P. 2006 (Summer). „Effect of spices on lipid metabolism in 1,2‑dimethylhydrazine-induced rat colon carcinogenesis“. J Med Food. 9(2):237–245.

11. Gagandeep Dhanalakshmi S., Méndiz, E., Rao, A. R., Kale, R. K. (2003). „Chemopreventive effects of Cuminum cyminum in chemically induced forestomach and uterine cervix tumors in murine model systems“. Nutr Cancer. 47(2):171–180.

12. Norwood, A. A., Tucci, M., Benghuzzi, H. 2007. „A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells“. Biomed Sci Instrum. 43:272–277.

13. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

14. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Kaposiho sarkom

1. Luca, T., Di Benedetto, G., Scuderi, M. R., Palumbo, M., Clementi, S., Bernardini, R., Cantarella, G. 2009 (Aug 15). „The CB(1)/CB(2) receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitro“. Eur J Pharmacol. 616(1-3):16–21.

2. Chao, C., Jacobson, L. P., Jenkins, F. J., Tashkin, D., Martínez-Maza, O., Roth, M. D., Ng, L., Margolick, J. B., Chmiel, J. S., Zhang, Z. F., Detels, R. 2009 (Feb). „Recreational drug use and risk of Kaposi’s Sarcoma in HIV- and HHV-8-coinfected homosexual men“. AIDS Res Hum Retroviruses. 25(2):149–156.

Leukémie a lymfom (obecně)

1. Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Altekruse, S. F., Kosary, C. L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M. P., Lewis, D. R., Chen, H. S., Feuer, E. J., Cronin, K. A., Edwards, B. K. (eds). „SEER Cancer Statistics Review, 1975–2008“. National Cancer Institute, Bethesda, Maryland. Dostupné z: http://seer.cancer.gov/csr /1975_2008/. Založeno na údajích programu SEER (Surveillance, Epidemiology, and End Results) z listopadu 2010, na internetových stránkách SEER uveřejněno 2011.

2. Světová zdravotnická organizace (WHO). 2002. „IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Non-Ionizing Radiation, Part 1: Static and Extremely Low-Frequency (ELF) Electric and Magnetic Fields. Volume 80“. Dostupné 16. dubna 2015. http://monographs.iarc.fr/ENG/Monographs/vol80/

Leukémie

1. Thomas Powles, Robert te Poele, Jonathan Shamash, Tracy Chaplin, David Propper, Simon Joel, Tim Oliver, Wai Man Liu. 2005 (Feb 1). „Cannabis-induced cytotoxicity in leukemic cell lines: The role of the cannabinoid receptors and the MAPK pathway“. Blood 105(3):1214–1221.

2. Liu, W. M., Scott, K. A., Shamash, J., Joel, S., Powles, T. B. 2008 (Sep). „Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach“. Leuk Lymphoma. 49(9):1800–1809.

3. Robert J. McKallip, Wentao Jia, Jerome Schlomer, James W. Warren, Prakash S. Nagarkatti, Mitzi Nagarkatti. 2006 (Sep). „Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression“. Mol Pharmacol. 70(3):897–908.

4. Wentao Jia, Venkatesh L. Hegde, Narendra P. Singh, Daniel Sisco, Steven Grant, Mitzi Nagarkatti, Prakash S. Nagarkatti. 2006. „Δ⁹-Tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria“. Mol Cancer Res 4(8):549–562.

5. Gustafsson, K., Wang, X., Severa, D., Eriksson, M., Kimby, E., Merup, M., Christensson, B., Flygare, J., Sander, B. 2008 (Sep 1). „Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation“. Int J Cancer. 123(5):1025–1033.

6. Tan, K. L., Koh, S. B., Ee, R. P., Khan, M., Go, M. L. 2012 (Sep). „Curcumin analogues with potent and selective anti-proliferative activity on acute promyelocytic leukemia: Involvement of accumulated misfolded nuclear receptor co-repressor (N-CoR) protein as a basis for selective activity“. ChemMedChem. 7(9):1567–1579.

Shan, Q. Q., Gong, Y. P., Guo, Y., Lin, J., Zhou, R. Q., Yang, X. 2012 (May). „Anti-tumor effect of tanshinone II A, tetrandrine, honokiol, curcumin, oridonin and paeonol on leukemia cell lines“. Sichuan Da Xue Xue Bao Yi Xue Ban. 43(3):362–366.

Kim, Y. S., Farrar, W., Colburn, N. H., Milner, J. A. 2012 (Jul). „Cancer stem cells: Potential target for bioactive food components“. J Nutr Biochem. 23(7):691–698.

7. Guenova, M. L., Michova, A., Balatzenko, G. N., Yosifov, D. Y., Stoyanov, N., Taskov, H., Berger, M. R., Konstantinov, S. M. 2012 (May). „A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia—a possible new therapeutic target“. Hematology 17(3):132–139.

8. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

Lymfom

1. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A., Flygare, J. (2009). „Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism“. Mol Cancer Res 7(7):1086–1098.

2. Mauro Maccarrone, Tatiana Lorenzon, Monica Bari, Gerry Melino, Alessandro Finazzi-Agrò. 2000. „Anandamide induces apoptosis in human cells via vanilloid receptors: Evidence for a protective role of cannabinoid receptors“. The Journal of Biological Chemistry 275:31938–31945.

3. Greene, William A., Jr., M.D. 1954. „Psychological factors and reticuloendothelial disease“. Psychosomatic Medicine 16:220–230.

4. Gouva, M., Damigos, D., Kaltsouda, A., Bouranta, P., Tsabouri, S., Mavreas, V., Bourantas, K. L. 2009. „Psychological risk factors in acute leukemia“. Interscientific Health Care 1:16–20.

5. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

6. Shishodia, S., Sethi, G., Ahn, K. S., Aggarwal, B. B. 2007 (Jun 30). „Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products“. Biochem Pharmacol. 74(1):118–130.

7. Goun, E., Cunningham, G., Solodnikov, S., Krasnykch, O., Miles, H. 2002 (Dec). „Antithrombin activity of some constituents from Origanum vulgare“. Fitoterapia 73(7-8):692–694.

Rakovina jater

1. Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., Díaz-Laviada, I. 2011 (Jul). „Anti-tumoral action of cannabinoids on hepatocellular carcinoma: Role of AMPK-dependent activation of autophagy“. Cell Death Differ. 18(7):1099–1111.

2. Giuliano, M., Pellerito, O., Portanova, P., Calvaruso, G., Antulli, A., De Blasio, A., Vento, R., Tesoriere, G. 2009 (Apr). „Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARgamma“. Biochimie. 91(4):457–465.

3. Tamtéž.

4. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., Mitchell, R. L. 1995 (Sep). „Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors“. Mol Pharmacol 48(3):443–450.

Rakovina plic

1. Gofman, John, M.D., Ph.D. 1999. Radiation from Medical Procedures in the Pathogenisis of Cancer and Ischemic Heart Disease (San Francisco: Center for Nuclear Responsibility, 1. vydání).

2. Victor Cohn. 1974 (Aug 18). „Cancer curb is studied: Doctors eye drug found in marijuana“. Washington Post.

Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L., Carchman, R. A. 1975 (Sep). „Antineoplastic activity of cannabinoids“. Journal of the National Cancer Institute 55(3).

3. Hashibe, M., Morgenstern, H., Cui, Y., Tashkin, D. P., Zhang, Z. F., Cozen, W., Mack, T. M., Greenland, S. 2006 (Oct). „Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-control study“. Cancer Epidemiol Biomarkers Prev. 15(10):1829–1834.

4. Ramer, R., Hinz, B. 2008 (Jan 2). „Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1“. J Natl Cancer Inst. 100(1):59–69.

5. Preet, A., Ganju, R. K., Groopman, J. E. 2008 (Jan 10). „Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo“. Oncogene 27(3):339–346.

6. Kissen, David M., Eysenck, H. J. 1962 (Apr-June). „Personality in male lung cancer patients“. Journal of Psychosomatic Research 6(2):123–127.

7. Grossarth-Maticek, Ronald, Kanazir, Dusan T., Schmidt, Peter, Vetter, Hermann. 1985. „Psychosocial and organic variables as predictors of lung cancer, cardiac infarct and apoplexy: Some differential predictors“. Personality and Individual Differences 6(3):313–321.

8. Quander-Blaznik, Jutta. 1991. „Personality as a predictor of lung cancer: A replication“. Personality and Individual Differences 12(2):125–130.

9. Banerjee, S., Panda, C. K., Das, S. 2006 (Aug). „Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer“. Carcinogenesis 27(8):1645–1654.

10. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

11. Shishodia, S., Sethi, G., Ahn, K. S., Aggarwal, B. B. 2007 (Jun 30). „Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products“. Biochem Pharmacol. 74(1):118–130.

Melanom (maligní rakovina kůže)

1. Grant, W. B. 2002 (Mar 15). „An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation“. Cancer 94(6):1867–1875.

2. Gonzalez-Rosales, F., Walsh, D. 1997. „Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol)“. Journal of Pain and Symptom Management 14(5):311–314.

3. Zutt, M., Hanssle, H., Emmert, S., Neumann, C., Kretschmer, L. 2006. „Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases“. Hautarzt 57(5):423–427.

4. Americká biotechnologická společnost Cannabis Science umístila na svých internetových stránkách článek nazvaný „Cannabis Science Updates Cancer Patient Progress As It Receives Verbal Confirmation By A Physician That Both Sites Of The Former Lesions Are Free Of Cancer Cells; Official Physician Documentation To Follow“. Dostupné 6. dubna 2015. www.cannabisscience.com/index.php/2011/497-cannabis-science-updates-cancer-patient-progress-as-it-receives-verbal-confirmation-by-a-physician-that-both-sites-of-the-former-lesions-are-free-of-cancer-cells-official-physician-documentation-to-follow

5. Jozsef Timar, Balazs Bani, Norbert Varga, Istvan Kenessey. „Cannabinoid receptor-1 modulation induces apoptosis of human melanoma cells“. Text prezentován 12. dubna 2008 v kalifornském San Diegu na 99. výročním setkání Americké asociace pro výzkum rakoviny (AACR).

6. Stačí zadat do internetového vyhledávače „Phoenix Tears“, nebo jméno jejího obhájce Ricka Simpsona, a získáte množství odkazů na různé servery a média, např.YouTube. Můžete rovněž zavítat přímo na stránky Phoenix Tears Foundation (www.phoenixtearsfoundation.com), nadace založené na podporu výzkumu konopí a léčby konopím, na domovskou stránku Ricka Simpsona (http://phoenixtears.ca/) nebo na stránky Patients Out of Time, dobrovolnické a neziskové dobročinné vzdělávací organizace fungující podle § 501(c)3 amerického zákona č. 26 (www.medicalcannabis.com/).

7. Lee, E. J., Jang, H. D. 2004. „Antioxidant activity and protective effect on DNA strand scission of rooibos tea (Aspalathus linearis)“. Biofactors 21 (1-4):285–292.

8. Marnewick, J., Joubert, E., Joseph, S., Swanevelder, S., Swart, P., Gelderblom, W. 2005 (Jun 28). „Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas“. Cancer Lett. 224(2):193–202.

9. Banerjee, S., Das, S. 2005 (Jul-Sep). „Anticarcinogenic effects of an aqueous infusion of cloves on skin carcinogenesis“. Asian Pac J Cancer Prev. 6(3):304–308.

10. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

Rakovina slinivky břišní

1. „World Health Organization (WHO) Tobacco-Free Initiative“. Dostupné 16. dubna 2015. www.who.int/tobacco/research/cancer/en/

2. Carracedo, A., Gironella, M., Lorente, M., Garcia, S., Guzmán, M., Velasco, G., Iovanna, J. L. 2006 (Jul 1). „Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress–related genes“. Cancer Res 66:6748–55.

3. Fogli, S., Nieri, P., Chicca, A., Adinolfi, B., Mariotti, V., Iacopetti, P., Breschi, M. C., Pellegrini, S. 2006 (Mar 20). „Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism“. FEBS Lett. 580(7):1733–1739.

4. Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., Kong, D., Ahmad, A., Li, Y., Padhye, S., Sarkar, F. H. 2012 (Jan 1). „Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression“. Cancer Res. 72(1):335–345.

5. Wu, Z. H., Chen, Z., Shen, Y., Huang, L. L., Jiang, P. 2011 (Aug). „Anti-metastasis effect of thymoquinone on human pancreatic cancer“. Yao Xue Xue Bao. 46(8):910–914.

Rakovina prostaty

1. Leitzmann, M. F., Platz, E. A., Stampfer, M. J., Willett, W. C., Giovannucci, E. 2004 (Apr 7). „Ejaculation frequency and subsequent risk of prostate cancer“. Journal of the American Medical Association. 291(13):1578–1586.

2. Melck, Dominique, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, Chiara Laezza, Maurizio Bifulco, Vincenzo Di Marzo. 2000. „Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation“. Endocrinology 141(1):118–126.

3. Sami Sarfaraz, Farrukh Afaq, Vaqar M. Adhami, Hasan Mukhtar. 2005 (Mar 1). „Cannabinoid receptor as a novel target for the treatment of prostate cancer“. Cancer Res 65:1635.

4. Czifra, G., Varga, A., Nyeste, K., Marincsák, R., Tóth, B. I., Kovács, I., Kovács, L., Bíró, T. 2009 (Apr). „Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma“. J Cancer Res Clin Oncol. 135(4):507–514.

5. Ullrich, Philip M., Ph.D., Susan K. Lutgendorf, Ph.D., Jane Leserman, Ph.D., Derek G. Turesky, BA, Karl J. Kreder, M.D. 2005. „Stress, hostility, and disease parameters of benign prostatic hyperplasia“. Psychosomatic Medicine 67:476–482.

6. White, Victoria M., Ph.D., Dallas R. English, Ph.D., Hamish Coates, Ph.D., Magdalena Lagerlund, Ph.D., Ron Borland, Ph.D., Graham G. Giles, Ph.D. 2007. „Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study“. Psychosomatic Medicine 69:667–674.

7. Sánchez, A. M., Sánchez, M. G., Malagarie-Cazenave, S., Olea, N., Díaz-Laviada, I. 2006 (Jan). „Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin“. Apoptosis 11(1):89–99.

8. Howard, E. W., Ling, M. T., Chua, C. W., Cheung, H. W., Wang, X., Wong, Y. C. 2007 (Mar 15). „Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer“. Clin Cancer Res. 13(6):1847–1856.

Rhabdomyosarkom

1. Kaefer, M., Rink, R. C. 2000 (Aug). „Genitourinary rhabdomyosarcoma“. Urologic Clinics of North America 27(3):471–87.

2. Grufferman, S., Schwartz, A. G., Ruymann, F. B., Maurer, H. M. 1993 (May). „Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children“. Cancer Causes Control. 4(3):217–224.

3. Oesch, S., Walter, D., Wachtel, M., Pretre, K., Salazar, M., Guzmán, M., Velasco, G., Schäfer, B. W. 2009 (Jun). „Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma“. Mol Cancer Ther. 9.

4. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

Rakovina kůže (nemelanomová)

1. Casanova, M. Llanos, Cristina Blázquez, Jesús Martínez-Palacio, Concepción Villanueva, M. Jesús Fernández-Aceñero, John W. Huffman, José L. Jorcano, Manuel Guzmán. 2003. „Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors“. J Clin Invest. 111(1):43–50.

2. Bíró, Tamás, Balázs I. Tóth, György Haskó, Ralf Paus, Pál Pacher. 2009 (Aug). „The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities“. Trends Pharmacol Sci. 30(8):411–420.

3. Lee, E. J., Jang, H. D. 2004. „Antioxidant activity and protective effect on DNA strand scission of rooibos tea (Aspalathus linearis)“. Biofactors 21(1-4):285–292.

4. Marnewick, J., Joubert, E., Joseph, S., Swanevelder, S., Swart, P., Gelderblom, W. 2005 (Jun 28). „Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas“. Cancer Lett. 224(2):193–202.

5. Banerjee, S., Panda, C. K., Das, S. 2006 (Aug). „Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer“. Carcinogenesis 27(8):1645–1654.

6. Banerjee, S., Das, S. 2005 (Jul-Sep). „Anticarcinogenic effects of an aqueous infusion of cloves on skin carcinogenesis“. Asian Pac J Cancer Prev. 6(3):304–308.

Rakovina štítné žlázy

1. Alford, Erika Masuda, M.D., Mimi I. Hu, M.D., Peter Ahn, M.D., Jeffrey P. Lamont, M.D. „Thyroid and parathyroid cancers“. In Cancer Management: A Multidisciplinary Approach. 13. vydání (CMPMedica, 2011).

2. Ligresti, Alessia, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano De Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco, Vincenzo Di Marzo. 2006 (Sep). „Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma“. JPET 318(3):1375–1387.

3. Cozzolino R., Calì, G., Bifulco, M., Laccetti, P. 2010 (Apr). „A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis“. Invest New Drugs 28(2):115–123.

4. Harland, W. H. 1900. „Notes on two cases of exophthalmic goiter appearing suddenly in men who have been in action“. Brit. M. J. 2:584.

5. Lidz, Theodore, M.D. 1949 (Jan 1). „Emotional factors in the etiology of hyperthyroidism“. Psychosomatic Medicine 11(1):28.

6. Mittelman, B. 1933. „Psychogenic factors and psychotherapy in hyperthyreosis and rapid heart imbalance“. J. Nerv. and Ment. Dis. 77:465.

7. Agnes, Conrad. 1934. „A psychiatric study of hyperthyroid patients“. J. Nerv. & Ment. Dis. 79:505.

Kardiovaskulární choroby

Onemocnění srdce

1. Xu, J. Q., Kochanek, K. D., Murphy, S. L., Tejada-Vera, B. „Deaths: Final data for 2007. National vital statistics reports web release; vol. 58 no. 19“. (Hyattsville, Maryland: National Center for Health Statistics. Uveřejněno v květnu 2010.)

2. Hayakawa, K., Mishima, K., Abe, K., Hasebe, N., Takamatsu, F., Yasuda, H., Ikeda, T., Inui, K., Egashira, N., Iwasaki, K., Fujiwara, M. 2004 (Oct 25). „Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism“. Neuroreport 15(15):2381–2385.

3. Shmist, Y. A., Goncharov, I., Eichler, M., Shneyvays, V., Isaac, A., Vogel, Z., Shainberg, A. 2006 (Feb). „Delta‑9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production“. Mol Cell Biochem 283(1-2):75–83.

4. Lamontagne, D., Lépicier, P., Lagneux, C., Bouchard, J. F. 2006 (Mar). „The endogenous cardiac cannabinoid system: A new protective mechanism against myocardial ischemia“. Arch Mal Coeur Vaiss. 99(3):242–246.

5. Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, Chaim Lotan. 2007. „Cannabidiol, a nonpsychoactive cannabis constituent, protects against myocardial ischemic reperfusion injury“. Am J Physiol Heart Circ Physiol 293:H3602–H3607.

6. Ashton, J. C., Smith, P. F. 2007 (Jul). „Cannabinoids and cardiovascular disease: The outlook for clinical treatments“. Curr Vasc Pharmacol. 5(3):175–185.

7. Resstel, L. B., Tavares, R. F., Lisboa, S. F., Joca, S. R, Corrêa, F. M., Guimarães, F. S. 2009 (Jan). „5-HT receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats“. Br J Pharmacol. 156(1):181–188.

8. Montecucco, F., Lenglet, S., Braunersreuther, V., Burger, F., Pelli, G., Bertolotto, M., Mach, F., Steffens, S. 2009 (May). „CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion“. J Mol Cell Cardiol. 46(5):612–620.

9. Hayakawa, K., Mishima, K., Abe, K., Hasebe, N., Takamatsu, F., Yasuda, H., Ikeda, T., Inui, K., Egashira, N., Iwasaki, K., Fujiwara, M. 2004 (Oct 25). „Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism“. Neuroreport 15(15):2381–2385.

10. Barefoot, J. C., Dahlstrom, W. G., Williams, R. B., Jr. 1983 (Mar). „Hostility, CHD incidence, and total mortality: A 25-year follow-up study of 255 physicians“. Psychosom Med. 45(1):59–63.

11. Tamtéž.

12. Harburg, Ernest, Ph.D., Mara Julius, ScD, Niko Kaciroti, Ph.D., Lillian Gleiberman, Ph.D., M. Anthony Schork, Ph.D. 2003. „Expressive/suppressive anger-coping responses, gender, and types of mortality: A 17-year follow-up (Tecumseh, Michigan, 1971–1988)“. Psychosomatic Medicine 65:588–597.

13. Williams, Janice E., Ph.D., MPH; Catherine C. Paton, MSPH; Ilene C. Siegler, Ph.D., MPH; Marsha L. Eigenbrodt, M.D., MPH; F. Javier Nieto, M.D., Ph.D.; Herman A. Tyroler, M.D. 2011. Anger Proneness Predicts Coronary Heart Disease Risk (American Heart Association, Inc.).

14. Harburg, Ernest, Ph.D., et al. 2003. „Expressive/suppressive anger-coping...“. Viz pozn. 12.

15. Everson, S. A., Goldberg, D. E., Kaplan, G. A., Cohen, R. D., Pukkala, E., Tuomilehto, J., Salonen, J. T. „Hopelessness and risk of mortality and incidence of myocardial infarction and cancer“. Psychosomatic Medicine 58(2):113–121.

16. Kubzansky, Laura D., Ph.D., David Sparrow, Dsc., Pantel Vokonas, M.D., Ichiro Kawachi, M.D. 2001. „Is the glass half empty or half full? A prospective study of optimism and coronary heart disease in the normative aging study“. Psychosomatic Medicine 63:910–916.

17. Abd-Allah, A. R., Al-Majed, A. A., Mostafa, A. M., Al-Shabanah, O. A., Din, A. G., Nagi, M. N. 2002. „Protective effect of Arabic gum against cardiotoxicity induced by doxorubicin in mice: A possible mechanism of protection“. J Biochem Mol Toxicol. 16(5):254–259.

18. Rudkowska, I., Jones, P. J. 2007 (May). „Functional foods for the prevention and treatment of cardiovascular diseases: Cholesterol and beyond“. Expert Rev Cardiovasc Ther. 5(3):477–490.

19. Suneetha, W. J., Krishnakantha, T. P. 2005 (May). „Cardamom extract as inhibitor of human platelet aggregation“. Phytother Res. 19(5):437–440.

20. Kaunitz, H. 1986 (Mar-Apr). „Medium-chain triglycerides (MCT) in aging and arteriosclerosis“. J Environ Pathol Toxicol Oncol. 6(3-4):115–121.

21. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

22. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

23. Okada, Y., Tanaka, K., Sato, E., Okajima, H. 2006 (Nov 21). „Kinetic and mechanistic studies of allicin as an antioxidant“. Org Biomol Chem. 4(22):4113–4117.

24. Fukao, H., Yoshida, H., Tazawa, Y., Hada, T. 2007 (Jan). „Antithrombotic effects of odorless garlic powder both in vitro and in vivo“. Biosci Biotechnol Biochem. 71(1):84–90.

25. Chuah, S. C., Moore, P. K., Zhu, Y. Z. 2007 (Nov). „S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulphide mediated pathway“. Am J Physiol Heart Circ Physiol. 293(5):H2693–2701.

26. Wu, C. X., Wei, X. B., Ding, H., Sun, X., Cheng, X. M. 2006 (Aug). „Protective effect of effective parts of Zingiber Officinale on vascular endothelium of the experimental hyperlipidemic rats“. Zhong Yao Cai. 29(8):810–813.

27. El-Bahai, M. N., Al-Hariri, M. T., Yar, T., Bamosa, A. O. 2009 (Jan 24). „Cardiac inotropic and hypertrophic effects of Nigella sativa supplementation in rats“. Int J Cardiol. 131(3):e115–117.

28. Hsieh, C. L., Peng, C. H., Chyau, C. C., Lin, Y. C., Wang, H. E., Peng, R. Y. 2007 (Apr 18). „Low-density lipoprotein, collagen, and thrombin models reveal that Rosmarinus officinalis L. exhibits potent antiglycative effects“. J Agric Food Chem. 55(8):2884–2891.

29. Deng, Y., Guo, Z. G., Zeng, Z. L., Wang, Z. 2002 (Aug). „Studies on the pharmacological effects of saffron (Crocus sativus L.)—A review“. Zhongguo Zhong Yao Za Zhi. 27(8):565–568.

30. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Vysoký krevní tlak

1. He, J., Whelton, P. K. 1997 (Sep). „Epidemiology and prevention of hypertension“. Med Clin North Am. 81(5):1077–1097.

2. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jr., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., Jr., Roccella, E. J. 2003. „The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report“. Journal of the American Medical Association 289:2560–2572.

3. Crawford, W. J., Merritt, J. C. 1979 (May). „Effects of tetrahydrocannabinol on arterial and intraocular hypertension“. Int J Clin Pharmacol Biopharm. 17(5):191–196.

4. Ho, W. S., Gardiner, S. M. 2009 (Jan). „Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats“. Br J Pharmacol. 156(1):94–104.

5. Ashton, J. C., Smith, P. F. 2007 (Jul). „Cannabinoids and cardiovascular disease: The outlook for clinical treatments“. Curr Vasc Pharmacol. 5(3):175–185.

6. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (July 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

7. Stupnice GWB-A a GWB-D převzaty z Dotazníku všeobecné pohody (General Well-being Schedule).

8. Jonas, Bruce S., ScM, Ph.D., Lando, James F., M.D., MPH. 2000. „Negative affect as a prospective risk factor for hypertension“. Psychosomatic Medicine 62:188–196.

9. Jonas, Bruce S., Ph.D., Franks, Peter, M.D., Ingram, Deborah D., Ph.D. 1997. „Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study“. Arch Fam Med. 6(1):43–49.

10. Lijing L. Yan, Ph.D., MPH; Kiang Liu, PhD; Karen A. Matthews, PhD; Martha L. Daviglus, M.D., PhD; T. Freeman Ferguson, MPH, MSPH; Catarina I. Kiefe, M.D., Ph.D. 2003. „Psychosocial factors and risk of hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study“. Journal of the American Medical Association 290(16):2138–2148.

11. Ostir, Glenn V., Ph.D., Ivonne M. Berges, Ph.D., Kyriakos S. Markides, Ph.D., Kenneth J. Ottenbacher, Ph.D. 2006. „Hypertension in older adults and the role of positive emotions“. Psychosomatic Medicine 68:727–733.

12. Richman, L. S., Kubzansky, L., Maselko, J., Kawachi, I., Choo, P., Bauer, M. 2005 (Jul). „Positive emotion and health: going beyond the negative“. Health Psychol. 24(4):422–429.

13. Mann, S. J., Delon, M. 1995 (Sep-Oct). „Improved hypertension control after disclosure of decades-old trauma“. Psychosomatic Medicine 57(5):501–505.

14. Khan, A. U., Gilani, A. H. 2006 (Dec). „Selective bronchodilatory effect of Rooibos tea (Aspalathus linearis) and its flavonoid, chrysoeriol“. Eur J Nutr. 45(8):463–469.

15. Rudkowska, I., Jones, P. J. 2007 (May). „Functional foods for the prevention and treatment of cardiovascular diseases: Cholesterol and beyond“. Expert Rev Cardiovasc Ther. 5(3):477–490.

16. Taubert, D., Roesen, R., Schomig, E. 2007 (Apr 9). „Effect of cocoa and tea intake on blood pressure: A meta-analysis“. Arch Intern Med. 167(7):626–634.

17. Lahlou, S., Tahraoui, A., Israili, Z., Lyoussi, B. 2007 (Apr 4). „Diuretic activity of the aqueous extracts of Carum carvi and Tanacetum vulgare in normal rats“. J Ethnopharmacol. 110(3):458–463.

18. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

19. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

20. Okada, Y., Tanaka, K., Sato, E., Okajima, H. 2006 (Nov 21). „Kinetic and mechanistic studies of allicin as an antioxidant“. Org Biomol Chem. 4(22): 4113–4117.

21. Fukao, H., Yoshida, H., Tazawa, Y., Hada, T. 2007 (Jan). „Antithrombotic effects of odorless garlic powder both in vitro and in vivo“. Biosci Biotechnol Biochem. 71(1):84–90.

Mozková mrtvice (cévní mozková příhoda neboli CMP)

1. Spojené státy americké zastoupené Ministerstvem zdravotnictví a sociálních služeb. Patent č. 09/674028, podaný 2. února 2001 (Aidan J. Hampson, Julius Axelrod, Maurizio Grimaldi). Patent 6630507 udělen 7. října 2003. Odhadovaný termín vypršení: 2021. Kanabinoidy jako antioxidanty a neuroprotektanty. www.patentstorm.us/patents/6630507.html

2. Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Irie, K., Fujioka, M., Orito, K., Abe, K., Hasebe, N., Egashira, N., Iwasaki, K., Fujiwara, M. 2007 (Sep). „Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism“. J Neurochem 102(5):1488–1496.

3. Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Ogata, A., Fujioka, M., Harada, K., Mishima, S., Orito, K., Egashira, N., Iwasaki, K., Fujiwara, M. 2007 (Mar 27). „Δ⁹-tetrahydrocannabinol (Δ⁹-THC) prevents cerebral infarction via hypothalamic-independent hypothermia“. Life Sci 80(16):1466–1471.

4. CES-D = Center for Epidemiological Studies Depression Scale.

5. Ostir, Glenn V., Ph.D., Kyriakos S. Markides, Ph.D., M. Kristen Peek, Ph.D., James S. Goodwin, M.D. 2001. „The association between emotional well-being and the incidence of stroke in older adults“. Psychosomatic Medicine 63:210–215.

6. Tamtéž.

7. Khan, A. U., Gilani, A. H. 2006 (Dec). „Selective bronchodilatory effect of Rooibos tea (Aspalathus linearis) and its flavonoid, chrysoeriol“. Eur J Nutr. 45(8):463–469.

8. Rudkowska, I., Jones, P. J. 2007 (May). „Functional foods for the prevention and treatment of cardiovascular diseases: Cholesterol and beyond“. Expert Rev Cardiovasc Ther. 5(3):477–490.

9. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

10. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

11. Okada, Y., Tanaka, K., Sato, E., Okajima, H. 2006 (Nov 21). „Kinetic and mechanistic studies of allicin as an antioxidant“. Org Biomol Chem. 4(22):4113–4117.

12. Fukao, H., Yoshida, H., Tazawa, Y., Hada, T. 2007 (Jan). „Antithrombotic effects of odorless garlic powder both in vitro and in vivo“. Biosci Biotechnol Biochem. 71(1):84–90.

13. Wu, C. X., Wei, X. B., Ding, H., Sun, X., Cheng, X. M. 2006 (Aug). „Protective effect of effective parts of Zingiber officinale on vascular endothelium of the experimental hyperlipidemic rats“. Zhong Yao Cai. 29(8):810–813.

Diabetes mellitus

1. Aubert, Ronald. 1995. Diabetes in America (2. vydání, National Institutes of Health, No. 95-1468), s. 3.

2. Tamtéž.

3. Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., Gallily, R. 2008 (Jan). „Cannabidiol arrests onset of autoimmune diabetes in NOD mice“. Neuropharmacology 54(1):244-249.

Také Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., Gallily, R. 2006 (Mar). „Cannabidiol lowers incidence of diabetes in non-obese diabetic mice“. Autoimmunity 39(2):143–151.

4. Zhang, F., Challapalli, S. C., Smith, P. J. 2009 (Aug). „Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(²⁺) influx in an in vitro model of diabetic neuropathy“. Neuropharmacology 57(2):88–96.

5. El-Remessy, Azza B., Mohamed Al-Shabrawey, Yousuf Khalifa, Nai-Tse Tsai, Ruth B. Caldwell, Gregory I. Liou. 2006. „Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes“. American Journal of Pathology 168:235–244.

6. Li, X., Kaminski, N. E., Fischer, L. J. 2001 (Apr). „Examination of the immunosuppressive effect of Δ⁹-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes“. Int Immunopharmacol. 1(4):699–712.

7. Bujalska, M. 2008. „Effect of cannabinoid receptor agonists on Streptozotocin-induced hyperalgesia in diabetic neuropathy“. Pharmacology 82(3):193–200.

8. Richman, L. S., Kubzansky, L., Maselko, J., Kawachi, I., Choo, P., Bauer, M. 2005 (Jul). „Positive emotion and health: going beyond the negative“. Health Psychol. 24(4):422–429.

9. Wales, J. K. 1995 (Feb). „Does psychological stress cause diabetes?“ Diabet Med. 12(2):109–12.

10. Ingerski, L. M., Anderson, B. J., Dolan, L. M., Hood, K. K. 2010 (Aug). „Blood glucose monitoring and glycemic control in adolescence: Contribution of diabetes-specific responsibility and family conflict“. J Adolesc Health. 47(2):191–197.

11. Ruzaidi, A., Amin, I., Nawalyah, A. G., Hamid, M., Faizul, H. A. 2005 (Apr 8). „The effect of Malaysian cocoa extract on glucose levels and lipid profiles in diabetic rats“. J Ethnopharmacol. 98(1-2):55–60.

12. Eddouks, M., Lemhadri, A., Michel, J. B. 2004 (Sep). „Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats“. J Ethnopharmacol. 94(1):143–148.

13. Rau, O., Wurglics, M., Dingermann, T., Abdel-Tawab, M., Schubert-Zsilavecz, M. 2006 (Nov). „Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor“. Pharmazie. 61(11):952–956.

14. Chaiyata, P., Puttadechakum, S., Komindr, S. 2003 (Sep). „Effect of chili pepper (Capsicum frutescens) ingestion on plasma glucose response and metabolic rate in Thai women“. J Med Assoc Thai. 86(9):854–860.

15. Kim, W., Khil, L. Y., Clark, R., Bok, S. H., Kim, E. E., Lee, S., Jun, H. S., Yoon, J. W. 2006 (Oct). „Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter“. Diabetologia. 49(10):2437–2448.

16. Subash, Babu P., Prabuseenivasan, S., Ignacimuthu, S. 2007 (Jan). „Cinnamaldehyde, a potential antidiabetic agent“. Phytomedicine 14(1):15–22.

17. Kannappan, S., Jayaraman, T., Rajasekar, P., Ravichandran, M. K., Anuradha, C. V. 2006 (Oct). „Cinnamon bark extract improves glucose metabolism and lipid profile in the fructose-fed rat“. Singapore Med J. 47(10):858–863.

18. Prasad, R. C., Herzog, B., Boone, B., Sims, L., Waltner-Law, M. 2005 (Jan 4). „An extract of Syzygium aromaticum represses genes encoding hepatic gluconeogenic enzymes“. J Ethnopharmacol. 96(1-2):295–301.

19. Srinivasan, K. 2005 (Sep). „Plant foods in the management of diabetes mellitus: Spices as beneficial antidiabetic food adjuncts“. Int J Food Sci Nutr. 56(6):399–414.

20. Sobenin, I. A., Nedosugova, L. V., Filatova, L. V., Balabolkin, M. I., Gorchakova, T. V., Orekhov, A. N. 2008 (Mar). „Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: The results of double-blinded placebo-controlled study“. Acta Diabetol. 45(1):1–6.

21. Al-Amin, Z. M., Thomson, M., Al-Qattan, K. K., Peltonen-Shalaby, R., Ali, M. 2006 (Oct). „Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in Streptozotocin-induced diabetic rats“. Br J Nutr. 96(4):660–666.

22. Ojewole, J. A. 2006 (Sep). „Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats“. Phytother Res. 20(9):764–772.

23. Yang, S., Na, M. K., Jang, J. P., Kim, K. A., Kim, B. Y., Sung, N. J., Oh, W. K., Ahn, J. S. 2006 (Aug). „Inhibition of protein tyrosine phosphatase 1B by lignans from Myristica fragrans“. Phytother Res. 20(8):680–682.

24. Lemhadri, A. Zeggwagh, N. A., Maghrani, M., Jouad, H., Eddouks, M. 2004 (Jun). „Anti-hyperglycaemic activity of the aqueous extract of Origanum vulgare growing wild in Tafilalet region“. J Ethnopharmacol. 92(2-3):251–256.

25. Hsieh, C. L., Peng, C. H., Chyau, C. C., Lin, Y. C., Wang, H. E., Peng, R. Y. 2007 (Apr 18). „Low-density lipoprotein, collagen, and thrombin models reveal that Rosmarinus officinalis L. exhibits potent antiglycative effects“. J Agric Food Chem. 55(8):2884–2891.

26. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

27. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J. Z., Xie, X. Q., Altmann, K. H., Karsak, M., Zimmer, A. 2008 (Jul 1). „Beta-caryophyllene is a dietary cannabinoid“. Proc Natl Acad Sci USA 105(26):9099–9104.

Horváth, Béla, Partha Mukhopadhyay, Malek Kechrid, Vivek Patel, Gali Tanchian, David A. Wink, Jürg Gertsch, Pál Pacher. 2012 (Apr 15). „β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner“. Free Radical Biology and Medicine 52(8):1325–1333.

Oční choroby a funkce oka

Věkem podmíněná makulární degenerace

1. Wei, Y., Wang, X., Wang, L. 2009 (Jun 14). „Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells“. Mol Vis. 15:1243–1251.

2. Abd-Allah, A. R., Al-Majed, A. A., Mostafa, A. M., Al-Shabanah, O. A., Din, A. G., Nagi, M. N. 2002. „Protective effect of Arabic gum against cardiotoxicity induced by doxorubicin in mice: A possible mechanism of protection“. J Biochem Mol Toxicol. 16(5):254–259.

3. Hermann, F., Ruschitzka, F., Spieker, L., Sudano, I., Noll, G., Corti, R. 2005 (Sep). „The sweet secret of dark chocolate“. Ther Umsch. 62(9):635–637.

4. Jayaprakasha, G. K., Ohnishi-Kameyama, M., Ono, H., Yoshida, M., Jaganmohan, Rao L. 2006 (Mar 8). „Phenolic constituents in the fruits of Cinnamomum zeylanicum and their antioxidant activity“. J Agric Food Chem. 54(5):1672–1679.

5. Jirovetz, L., Buchbauer, G., Stoilova, I., Stoyanova, A., Krastanov, A., Schmidt, E. „Chemical composition and antioxidant properties of clove leaf essential oil“. 2006 (Aug 23). J Agric Food Chem. 54(17):6303–6307.

6. Satyanarayana, S., Sushruta, K., Sarma, G. S., Srinivas, N., Subba Raju, G. V. 2004. „Antioxidant activity of the aqueous extracts of spicy food additives—evaluation and comparison with ascorbic acid in in-vitro systems“. J Herb Pharmacother. 4(2):1–10.

7. Birdane, F. M., Cemek, M., Birdane, Y. O., Gülçin, I., Büyükokurolu, M. E. 2007 (Jan 28). „Beneficial effects of Foeniculum vulgare on ethanol-induced acute gastric mucosal injury in rats“. World J Gastroenterol. 13(4):607–611.

8. Siddaraju, M. N., Dharmesh, S. M. 2007 (Mar). „Inhibition of gastric H+, K+-ATPase and Helicobacter pylori growth by phenolic antioxidants of Zingiber officinale“. Mol Nutr Food Res. 51(3):324–332.

9. Ivanova, D., Gerova, D., Chervenkov, T., Yankova, T. 2005 (Jan 4). „Polyphenols and antioxidant capacity of Bulgarian medicinal plants“. J Ethnopharmacol. 96(1-2):145–150.

10. Venkatesan, N., Punithavathi, D., Babu M. 2007. „Protection from acute and chronic lung diseases by curcumin“. Adv Exp Med Biol. 595:379–405.

11. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Glaukom

1. Hepler, R. S., Frank, I. R. 1971. „Marihuana smoking and intraocular pressure“. Journal of the American Medical Association 217(10):1392.

2. Crawford, W. J., Merritt, J. C. 1979 (May). „Effects of tetrahydrocannabinol on arterial and intraocular hypertension“. Int J Clin Pharmacol Biopharm. 17(5):191–196.

3. Song, Z. H., Slowey, C. A. 2000 (Jan). „Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55,212-2“. J Pharmacol Exp Ther. 292(1):136–139.

4. Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., Robson, P. J. 2006. „Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study“. J Glaucoma 15(5):349–353.

5. Plange, N., Arend, K. O., Kaup, M., Doehmen, B., Adams, H., Hendricks, S., Cordes, A., Huth, J., Sponsel, W. E., Remky, A. 2007 (Jan). „Dronabinol and retinal hemodynamics in humans“. Am J Ophthalmol. 143(1):173–174.

6. Green, K. 1998 (Nov). „Marijuana smoking vs cannabinoids for glaucoma therapy“. Arch Ophthalmol. 116(11):1433–1437.

7. Merritt, J. C., Perry, D. D., Russell, D. N., Jones, B. F. 1981 (Aug-Sep). „Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma“. J Clin Pharmacol. 21(8-9 Suppl):467S–471S.

8. Merritt, J. C., Crawford, W. J., Alexander, P. C., Anduze, A. L., Gelbart, S. S. 1980. „Effect of marihuana on intraocular and blood pressure in glaucoma“. Ophthalmology 87(3):222–228.

9. Cooler, P., Gregg, J. M. 1977 (Aug). „Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans“. South Med J. 70(8):951–954.

10. Berger, Allan S., M.D., Simel, Paul J., M.D. 1958. „Effect of hypnosis on intraocular pressure in normal and glaucomatous subjects“. Psychosomatic Medicine 20:321–327.

Zlepšení nočního vidění

1. Russo, E. B., Merzoukib, A., Molero, J., Mesab, K., Freyd, A., Bach, P. J. 2004 (Jul). „Cannabis improves night vision: A case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco“. J Ethnopharmacol. 93(1):99–104.

Uveitida

1. Toguri, J. T., Lehmann, C., Laprairie, R. B., Szczesniak, A. M., Zhou, J., Denovan-Wright, E. M., Kelly, M. E. 2014 (Mar). „Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis“. Br J Pharmacol. 171(6):1448–1461.

2. El-Remessy, A. B., Tang, Y., Zhu, G., Matragoon, S., Khalifa, Y., Liu, E. K., Liu, J. Y., Hanson, E., Mian, S., Fatteh, N., Liou, G. I. 2008. „Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: Critical role of p38 MAPK activation“. Mol Vis. 14:2190–2203.

3. Xu, H., Cheng, C. L., Chen, M., Manivannan, A., Cabay, L., Pertwee, R. G., Coutts, A., Forrester, J. V. 2007 (Sep). „Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis“. J Leukoc Biol. 82(3):532–541.

Horečka a regulace teploty

1. Khalid Benamar, Menachem Yondorf, Joseph J. Meissler, Ellen B. Geller, Ronald J. Tallarida, Toby K. Eisenstein, Martin W. Adler. 2007 (Mar). „A novel role of cannabinoids: Implication in the fever induced by bacterial lipopolysaccharide“. JPET 320(3):1127–1133.

2. Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Ogata, A., Fujioka, M., Harada, K., Mishima, S., Orito, K., Egashira, N., Iwasaki, K., Fujiwara, M. 2007 (Mar 27). „Δ⁹-tetrahydrocannabinol (Δ⁹-THC) prevents cerebral infarction via hypothalamic-independent hypothermia“. Life Sci. 80(16):1466–1471.

Fibromyalgie

1. Chakrabarty, S., Zoorob, R. 2007 (Jul 15). „Fibromyalgia“. Am Fam Physician. 76(2):247–254.

2. Skrabek, R. Q., Galimova, L., Ethansand, Daryl K. 2008 (Feb). „Nabilone for the treatment of pain in fibromyalgia“. J Pain. 9(2):164–173.

3. Ware, M. A., Fitzcharles, M. A., Joseph, L., Shir, Y. 2010 (Feb 1). „The effects of Nabilone on sleep in fibromyalgia: Results of a randomized controlled trial“. Anesth Analg. 110(2):604–610.

4. Burstein, Sumner H., Zurier, Robert B. 2009 (Mar). „Cannabinoids, endocannabinoids, and related analogs in inflammation“. AAPS J. 11(1):109–119.

5. Schweinhardt, P., Sauro, K. M., Bushnell, M. C. 2008 (Oct). „Fibromyalgia: A disorder of the brain?“ Neuroscientist 14(5):415–421.

6. Zautra, Alex J., Ph.D., Robert Fasman, M.A., John W. Reich, Ph.D., Peter Harakas, M.Sc., Lisa M. Johnson, M.A., Maureen E. Olmsted, Ph.D., Mary C. Davis, Ph.D. 2005. „Fibromyalgia: Evidence for deficits in positive affect regulation“. Psychosomatic Medicine 67:147–155.

7. Broderick, Joan E., Ph.D., Doerte U. Junghaenel, M.A., Joseph E. Schwartz, Ph.D. 2005. „Written emotional expression produces health benefits in fibromyalgia patients“. Psychosomatic Medicine 67:326–334.

8. Walker, E. A., Keegan, D., Gardner, G., Sullivan, M., Bernstein, D., Katon, W. J. 1997. „Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: II. Sexual, physical, and emotional abuse and neglect“. Psychosomatic Medicine 59(6):572–577.

9. Chenchen Wang, M.D., MPH, Christopher H. Schmid, Ph.D., Ramel Rones, B.S., Robert Kalish, M.D., Janeth Yinh, M.D., Don L. Goldenberg, M.D., Yoojin Lee, M.S., Timothy McAlindon, M.D., MPH. 2010. „A randomized trial of Tai Chi for fibromyalgia“. N Engl J Med 363:743–775.

Hemoroidy

1. Donovan, M. 1845 (Jan 1). „On the physical and medicinal qualities of Indian hemp (Cannabis indica); with observations on the best mode of administration, and cases illustrative of its powers“. Dublin Journal of Medical Science (1836–1845) 26(3):368–402.

2. Shah, N. C., Joshi, M. C. 1971. „An ethnobotanical study of the Kumaon region of India“. Economic Botany 25(4):414–422.

3. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (July 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

4. Bliss, D. Z., Jung, H. J., Savik, K., Lowry, A., LeMoine, M., Jensen, L., Werner, C., Schaffer, K. 2001 (Jul-Aug). „Supplementation with dietary fiber improves fecal incontinence“. Nurs Res. 50(4):203–213.

5. Elwakeel, H. A., Moneim, H. A., Farid, M., Gohar, A. A. 2007 (Jul). „Clove oil cream: A new effective treatment for chronic anal fissure“. Colorectal Dis. 9(6):549–552.

6. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

Zánětlivá onemocnění (obecně)

1. Horváth, Béla, Partha Mukhopadhyay, Malek Kechrid, Vivek Patel, Gali Tanchian, David A. Wink, Jürg Gertsch, Pál Pacher. 2012 (April 15). „β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner“. Free Radical Biology and Medicine 52(8):1325–1333.

2. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

3. Tamtéž.

4. Khanna, D., Sethi, G., Ahn, K. S., Pandey, M. K., Kunnumakkara, A. B., Sung, B., Aggarwal, A., Aggarwal, B. B. 2007 (Jun). „Natural products as a gold mine for arthritis treatment“. Curr Opin Pharmacol. 7(3):344–351.

5. Tekeoglu, I., Dogan, A., Ediz, L., Budancamanak, M., Demirel, A. 2007 (Sep). „Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models“. Phytother Res. 21(9):895–897.

6. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Artritida

1. Hootman, J., Bolen, J., Helmick, C., Langmaid, G. 2006. „Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2003–2005“. MMWR 55(40):1089–1092.

2. Wolfe, Sidney M., M.D., Larry D. Sasich, Pharm.D., MPH, Rose-Ellen Hope, R.Ph., Public Citizen’s Health Research Group. 1999. Worst Pills, Best Pills—A Consumer’s Guide to Avoiding Drug-Induced Death or Illness (New York: Pocket Books).

3. Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., M. Feldmann. 2000 (Aug 15). „The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis“. Proc Natl Acad Sci USA 97(17):9561–9566.

4. Burstein, Sumner. 2005 (Mar). „Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials“. AAPS J. 7(1):E143–E148.

5. Schuelert, N., Johnson, M. P., Oskins, J. L., Jassal, K., Chambers, M. G., McDougall, J. J. 2011 (May). „Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis“. Pain. 152(5):975–981.

6. Schiel, K. A. 1999 (Oct). „A proposed psychosomatic etiologic model for rheumatoid arthritis“. Med Hypotheses. 53(4):305–314.

7. Wise, B. L., Niu, J., Zhang, Y., Wang, N., Jordan, J. M., Choy, E., Hunter, D. J. 2010 (Jul). „Psychological factors and their relation to osteoarthritis pain“. Osteoarthritis Cartilage. 18(7):883–887.

8. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

9. Khanna, D., Sethi, G., Ahn, K. S., Pandey, M. K., Kunnumakkara, A. B., Sung, B., Aggarwal, A., Aggarwal, B. B. 2007 (Jun). „Natural products as a gold mine for arthritis treatment“. Curr Opin Pharmacol. 7(3):344–351.

10. Haffor, A. S. 2010 (Mar). „Effect of myrrh (Commiphora molmol) on leukocyte levels before and during healing from gastric ulcer or skin injury“. J Immunotoxicol. 7(1):68–75.

11. Tekeoglu, I., Dogan, A., Ediz, L., Budancamanak, M., Demirel, A. 2007 (Sep). „Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models“. Phytother Res. 21(9):895–897.

Ateroskleróza

1. Lu, Dai, Kiran Vemuri, V., Duclos, Richard I., Jr., Makriyannis, Alexandros. 2006 (Jul). „The cannabinergic system as a target for anti-inflammatory therapies“. Current Topics in Medicinal Chemistry 6(13):1401–1426. Bentham Science Publishers.

2. Takeda, S., Usami, N., Yamamoto, I., Watanabe, K. 2009 (Aug). „Cannabidiol-2’,6’-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15 lipoxygenase inhibitor“. Drug Metab Dispos. 37(8):1733–1737.

3. Zhao, Y., Yuan, Z., Liu, Y., Xue, J., Tian, Y., Liu, W., Zhang, W., Shen, Y., Xu, W., Liang, X., Chen, T. 2010 (Jan). „Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules“. J Cardiovasc Pharmacol. 9.

4. Miller, T. Q., Smith, T. W., Turner, C. W., Guijarro, M. L., Hallet, A. J. 1996. „A meta-analytic review of research on hostility and physical health“. Psychol Bull. 119:322–348.

5. Whiteman, Martha C., Ph.D., Ian J. Deary, F. Gerald R. Fowkes. 2000 (Sep-Oct). „Personality and social predictors of atherosclerotic progression: Edinburgh Artery Study“. Psychosomatic Medicine 62(5):703–714.

6. Roy, Brita, M.D., MPH, M.S., Ana V. Diez-Roux, M.D., Ph.D., Teresa Seeman, Ph.D., Nalini Ranjit, Ph.D., Steven Shea, M.D., Mary Cushman, M.D. 2010 (Feb/Mar). „Association of optimism and pessimism with inflammation and hemostasis in the Multi-Ethnic Study of Atherosclerosis (MESA)“. Psychosomatic Medicine 72(2):134–140.

7. Rozanski, Alan, M.D., Heidi Gransar, M.S., Laura D. Kubzansky, Ph.D., Nathan Wong, M.D., Leslee Shaw, Ph.D., Romalisa Miranda-Peats, MPH, Louise E. Thomson, MBChB, Sean W. Hayes, M.D., John D. Friedman, M.D., MPH, Daniel S. Berman, M.D. 2011 (Jan). „Do psychological risk factors predict the presence of coronary atherosclerosis?“ Psychosomatic Medicine 73(1):7–15.

8. Rudkowska, I., Jones, P. J. 2007 (May). „Functional foods for the prevention and treatment of cardiovascular diseases: Cholesterol and beyond“. Expert Rev Cardiovasc Ther. 5(3):477–490.

9. Suneetha, W. J., Krishnakantha, T. P. 2005 (May). „Cardamom extract as inhibitor of human platelet aggregation“. Phytother Res. 19(5):437–440.

10. Kaunitz, H. 1986 (Mar-Apr). „Medium-chain triglycerides (MCT) in aging and arteriosclerosis“. J Environ Pathol Toxicol Oncol. 6(3-4):115–21.

11. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

12. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

13. Okada, Y., Tanaka, K., Sato, E., Okajima, H. 2006 (Nov 21). „Kinetic and mechanistic studies of allicin as an antioxidant“. Org Biomol Chem. 4(22):4113–4117.

14. Fukao, H., Yoshida, H., Tazawa, Y., Hada, T. 2007 (Jan). „Antithrombotic effects of odorless garlic powder both in vitro and in vivo“. Biosci Biotechnol Biochem. 71(1):84–90.

15. Hsieh, C. L., Peng, C. H., Chyau, C. C., Lin, Y. C., Wang, H. E., Peng, R. Y. 2007 (Apr 18). „Low-density lipoprotein, collagen, and thrombin models reveal that Rosmarinus officinalis L. exhibits potent antiglycative effects“. J Agric Food Chem. 55(8):2884–2891.

16. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

(Intersticiální) cystitida

1. Krenn, H., Daha, L. K., Oczenski, W., Fitzgerald, R. D. 2003. „A case of cannabinoid rotation in a young woman with chronic cystitis“. J Pain Symptom Manage. 25(1):3–4.

2. Twiss, Christian, Kilpatrick, Lisa, Craske, Michelle, Buffington, C. A. Tony, Ornitz, Edward, Rodríguez, Larissa V., Mayer, Emeran A., Naliboff, Bruce D. 2009. „Increased acoustic startle responses in IBS patients during abdominal and non-abdominal threat“. The Journal of Urology 181(5):2127–2133.

3. Theoharides, T. C., Whitmore, K., Stanford, E., Moldwin, R., O’Leary, M. P. 2008 (Dec). „Interstitial cystitis: Bladder pain and beyond“. Expert Opin Pharmacother. 9(17):2979–2994.

Revmatoidní artritida

1. Blake, D. R., Robson, P., Ho, M., Jubb, R. W., McCabe, C. S. 2006. „Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis“. Rheumatology 45(1):50–52.

2. Lu, Dai, Kiran Vemuri, V., Duclos, Richard I., Jr., Makriyannis, Alexandros. 2006 (Jul). „The cannabinergic system as a target for anti-inflammatory therapies“. Current Topics in Medicinal Chemistry 6(13):1401–1426(26). Bentham Science Publishers.

3. Burstein, Sumner H., Zurier, Robert B. 2009 (Mar). „Cannabinoids, endocannabinoids, and related analogs in inflammation“. AAPS J. 11(1):109–119.

4. Cobb, Sidney, M.D., Stanislav V. Kasl, Ph.D., Edith Chen, M.A., Roger Christenfeld, M.A. 1965 (Dec). „Some psychological and social characteristics of patients hospitalized for rheumatoid arthritis, hypertension, and duodenal ulcer“. Journal of Chronic Diseases 18(12):1259–1278.

5. Cheren, Stanley, M.D., Levitan, Harold, M.D. 1989. „Chapter 4. Onset Situation in Three Psychosomatic Illnesses“ in Psychosomatic Medicine: Theory, Physiology and Practice (Madison, Connecticut: International University Press, Inc., 1. díl).

6. Johnson, Adelaide, M.D., Shapiro, Louis B., M.D., Alexander, Franz, M.D. „Preliminary Report on a Psychosomatic Study of Rheumatoid Arthritis“. Text prezentován 3. května 1947 na výročním setkání Americké společnosti pro výzkum psychosomatických problémů v Atlantic City (New Jersey).

7. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

8. Khanna, D., Sethi, G., Ahn, K. S., Pandey, M. K., Kunnumakkara, A. B., Sung, B., Aggarwal, A., Aggarwal, B. B. 2007 (Jun). „Natural products as a gold mine for arthritis treatment“. Curr Opin Pharmacol. 7(3):344–351.

9. Tekeoglu, I., Dogan, A., Ediz, L., Budancamanak, M., Demirel, A. 2007 (Sep). „Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models“. Phytother Res. 21(9):895–897.

Gastroezofageální reflux (GER)

1. Beaumont, H., Jensen, J., Carlsson, A., Ruth, M., Lehmann, A., Boeckxstaens, G. E. 2009 (Jan). „Effect of Delta(9)-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans“. Br J Pharmacol. 156(1):153–162.

2. Naliboff, Bruce D., Ph.D., Minou Mayer, M.A., MFT, Ronnie Fass, M.D., Leah Z. Fitzgerald, RN, M.S., Lin Chang, M.D., Roger Bolus, Ph.D., Emeran A. Mayer, M.D. 2004. „The effect of life stress on symptoms of heartburn“. Psychosomatic Medicine 66:426–434.

3. Sharma, Abhishek, M.D., Ph.D., Lukas Van Oudenhove, M.D., Ph.D., Peter Paine, M.D., Ph.D., Lloyd Gregory, Ph.D., Qasim Aziz, M.D., Ph.D. 2010 (Oct). „Anxiety increases acid-induced esophageal hyperalgesia“. Psychosomatic Medicine 72(8):802–809.

Nespecifické střevní záněty (IBS)

1. Ford, A. C., Talley, N. J., Spiegel, B. M., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M., Moayyedi, P. „Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis“. BMJ 337:a2313.

2. Izzo, A. A., Sharkey, K. A. 2010 (Apr). „Cannabinoids and the gut: New developments and emerging concepts“. Pharmacol Ther. 126(1):21–38.

3. Lu, Dai, Kiran Vemuri, V., Duclos, Richard I., Jr., Makriyannis, Alexandros. 2006 (Jul). „The cannabinergic system as a target for anti-inflammatory therapies“. Current Topics in Medicinal Chemistry 6(13):1401–1426(26). Bentham Science Publishers.

4. Storr, M. A., Keenan, C. M., Emmerdinger, D., Zhang, H., Yüce, B., Sibaev, A., Massa, F., Buckley, N. E., Lutz, B., Göke, B., Brand, S., Patel, K. D., Sharkey, K. A. 2008 (Aug). „Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB(1) and CB(2) receptors“. J Mol Med. (Berl). 86(8):925–936.

5. Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F., Izzo, A. 2008 (Jul). „Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice“. Br J Pharmacol. 154(5):1001–1008.

6. Kaptchuk, Ted J., Elizabeth Friedlander, John M. Kelley, M. Norma Sanchez, Efi Kokkotou, Joyce P. Singer, Magda Kowalczykowski, Franklin G. Miller, Irving Kirsch, Anthony J. Lembo. 2010 (Dec 22). „Placebos without deception: A randomized controlled trial in irritable bowel syndrome“. PloS ONE 5(12):e15591.

Kaptchuk, Ted J., John M. Kelley, Lisa A. Conboy, Roger B. Davis, Catherine E. Kerr, Eric E. Jacobson, Irving Kirsch, Rosa N. Schyner, Bong Hyun Nam, Long T. Nguyen, Min Park, Andrea L. Rivers, Claire McManus, Efi Kokkotou, Douglas A. Drossman, Peter Goldman, Anthony J. Lembo. 2008 (Apr). „Components of placebo effect: Randomized controlled trial in patients with irritable bowel syndrome“. BMJ 336:999.

7. Whitehead, W. E., Palsson, O., Jones, K. R. 2002 (Apr). „Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?“ Gastroenterology 122(4):1140–1156.

9. Tamtéž.

10. Tamtéž.

11. Bliss, D. Z., Jung, H. J., Savik, K., Lowry, A., LeMoine, M., Jensen, L., Werner, C., Schaffer, K. 2001 (Jul-Aug). „Supplementation with dietary fiber improves fecal incontinence“. Nurs Res. 50(4):203–213.

12. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

13. Hanai, H., Iida, T., Takeuchi, K., Watanabe, F., Maruyama, Y., Andoh, A., Tsujikawa, T., Fujiyama, Y., Mitsuyama, K., Sata, M., Yamada, M., Iwaoka, Y., Kanke, K., Hiraishi, H., Hirayama, K., Arai, H., Yoshii, S., Uchijima, M., Nagata, T., Koide, Y. 2006 (Dec). „Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial“. Clin Gastroenterol Hepatol. 4(12):1502–1506.

Pankreatitida

1. Michalski, Christoph W., Milena Maier, Mert Erkan, Danguole Sauliunaite, Frank Bergmann, Pal Pacher, Sandor Batkai, Nathalia A. Giese, Thomas Giese, Helmut Friess, Jörg Kleeff. 2008. „Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells“. PLoS ONE 3(2):e1701.

2. Dembiński, A., Warzecha, Z., Ceranowicz, P., Warzecha, A. M., Pawlik, W. W., Dembiński, M., Rembiasz, K., Sendur, P., Kuśnierz-Cabala, B., Tomaszewska, R., Chowaniec, E., Konturek. P. C. 2008 (Sep 4). „Dual, time-dependent deleterious and protective effect of anandamide on the course of cerulein-induced acute pancreatitis. Role of sensory nerves“. Eur J Pharmacol. 591(1-3):284–292.

3. Nakai, Y., Araki, T., Takahashi, S., Shimada, A., Nakagawa, T. 1983. „Chronic pancreatitis as psychosomatic disorder“. Psychother Psychosom. 39(4):201–212.

4. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Periodontitida

1. Napimoga, M. H., Benatti, B. B., Lima, F. O., Alves, P. M., Campos, A. C., Pena-Dos-Santos, D. R., Severino, F. P., Cunha, F. Q., Guimarães, F. S. 2009 (Feb). „Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats“. Int Immunopharmacol. 9(2):216–222.

2. Vitaliano, Peter P., Ph.D., Rutger Persson, DDS, Ph.D., Asuman Kiyak, Ph.D., Hardeep Saini, B.S., Diana Echeverria, Ph.D. 2005. „Caregiving and gingival symptom reports: Psychophysiologic mediators“. Psychosomatic Medicine 67:930–938.

3. Tamtéž.

4. Gazzani, G., Daglia, M., Papetti, A. 2012 (Apr). „Food components with anticaries activity“. Curr Opin Biotechnol. 23(2):153–159.

Nespavost

1. Fujimori, M., Himwich, H. E. 1973. „Delta sup(9) Tetrahydrocannabinol and the sleep wakefulness cycle“. Physiology and Behavior 11(3):291–295.

Freemon, F. R. 1974. „The effect of Delta sup(9) tetrahydrocannabinol on sleep“. Psychopharmacologia 35(1):39–44.

Adams, P. M., Barratt, E. S. 1975. „Effect of chronic marijuana administration on stages of primate sleep wakefulness. Biological Psychiatry 10(3):315–322.

Feinberg, I., Jones, R., et al. 1975. „Effects of high-dosage delta-9-tetrahydrocannabinol on sleep patterns in man“. Clinical Pharmacology and Therapeutics 17(4):458–466.

Feinberg, I., Jones, R., et al. 1976. „Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns“. Clinical Pharmacology and Therapeutics 19(6):782–794.

Freemon, F. R. 1982. „The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers“. Drug and Alcohol Dependence 10(4):345–353.

2. Nicholson, A. N., Turner, C., Stone, B. M., Robson, P. J. 2004 (Jun). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults“. J Clin Psychopharmacol. 24(3):305–313.

3. Fernández-Mendoza, Julio, M.S., Antonio Vela-Bueno, M.D., Alexandros N. Vgontzas, M.D., María José Ramos-Platón, Ph.D., Sara Olavarrieta-Bernardino, M.Sc., Edward O. Bixler, Ph.D., Juan José De la Cruz-Troca, MSc. 2010 (May). „Cognitive-emotional hyperarousal as a premorbid characteristic of individuals vulnerable to insomnia“. Psychosomatic Medicine 72(4):397–403.

Libido

1. Parker, R. C., Lux. 2008 (Jun). „Psychoactive plants in Tantric Buddhism; Cannabis and datura use in Indo-Tibetan Esoteric Buddhism“. Erowid Extracts 14:6–11.

2. Sam’l O. L. Potter, M.A., M.D., MRCP (Lond.) 1892. A Compend of Materia Medica and Therapeutics and Prescription Writing; with especial references to the physiological actions of drugs (Philadelphia: P. Blakiston, Son & Co.), s. 40. Založeno na poslední revizi 5. vydání díla U.S. Pharmacopeia.

3. Mahler, S. V., Smith, K. S., Berridge, K. C. 2007 (Nov). „Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances ‘liking’ of a sweet reward“. Neuropsychopharmacology 32(11):2267–2278.

4. Kassi, E., Papoutsi, Z., Fokialakis, N., Messari, I., Mitakou, S., Moutsatsou, P. 2004 (Nov 17). „Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties“. J Agric Food Chem. 52(23):6956–6961.

5. Preuss, H. G., Echard, B., Polansky, M. M., Anderson, R. 2006 (Apr). „Whole cinnamon and aqueous extracts ameliorate sucrose-induced blood pressure elevations in spontaneously hypertensive rats“. J Am Coll Nutr. 25(2): 144–150.

6. Tajuddin Shamshad, Ahmad, Abdul Latif, Iqbal A. Qasmi. 2003 (Oct 20). „Myristica fragrans Houtt. (nutmeg) and Syzygium aromaticum (L) Merr. & Perry (clove) in male mice: A comparative study“. BMC Complementary and Alternative Medicine 3:6.

7. Qureshi, S., Shah, A. H., Tariq, M., Ageel, A. M. 1989. „Studies on herbal aphrodisiacs used in Arab system of medicine“. Am J Chin Med. 17(1-2):57–63.

8. Kamtchouing, P., Mbongue, G. Y., Dimo, T., Watcho, P., Jatsa, H. B., Sokeng, S. D. 2002 (May). „Effects of Aframomum melegueta and Piper guineense on sexual behaviour of male rats“. Behav Pharmacol. 13(3):243–247.

9. Dording, C. M., Fisher, L., Papakostas, G., Farabaugh, A., Sonawalla, S., Fava, M., Mischoulon, D. 2008 (Fall). „A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction“. CNS Neurosci Ther. 14(3):182–191.

10. Tajuddin, Ahmad S. et al. 2003. „Aphrodisiac activity of 50% ethanolic extracts of Myristica fragrans...“. Viz pozn. 6.

Plicní choroby

Astma

1. Tashkin, D. P., Shapiro, B. J., Frank, I. M. 1974 (Apr). „Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects“. Am Rev Respir Dis. 109(4):420–428.

2. Tashkin, D. P., Shapiro, B. J., Lee, Y. E., Harper, C. E. 1975 (Sep). „Effects of smoked marijuana in experimentally induced asthma“. Am Rev Respir Dis. 112(3):377–386.

3. Williams, S. J., Hartley, J. P., Graham, J. D. 1976. „Bronchodilator effect of Δ¹-tetrahydrocannabinol administered by aerosol of asthmatic patients“. Thorax 31(6):720–723.

4. Tashkin, D. P., Reiss, S., Shapiro, B. J., Calvarese, B., Olsen, J. L., Lodge, J. W. 1977 (Jan). „Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects“. Am Rev Respir Dis. 115(1):57–65.

5. Hartley, J. P., Nogrady, S. G., Seaton, A. 1978 (Jun). „Bronchodilator effect of Δ¹-tetrahydrocannabinol“. Br J Clin Pharmacol. 5(6):523–525.

6. Gong, H., Jr., Tashkin, D. P., Calvarese, B. 1983. „Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects“. Journal of Clinical Pharmacology 23(4):127–133.

7. Lu, Dai, Kiran Vemuri, V., Duclos, Richard I., Jr., Makriyannis, Alexandros. 2006 (Jul). „The cannabinergic system as a target for anti-inflammatory therapies“. Current Topics in Medicinal Chemistry 6(13):1401–1426(26). Bentham Science Publishers.

9. Monday, J., Montplaisir, J., Malo, J. L. 1987 (May). „Dream process in asthmatic subjects with nocturnal attacks“. Am J Psychiatry 144(5):638–640.

10. Wood, James, M., Bootzin, Richard R., Quan, Stuart F., Klink, Mary E. 1993 (Dec). „Prevalence of nightmares among patients with asthma and chronic obstructive airways disease“. Dreaming 3(4):231–241.

11. William Ernest Henley (1849–1903). „Invictus“.

12. Boskabady, M. H., Ramazani-Assari, M. 2001 (Jan). „Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s)“. J Ethnopharmacol. 74(1):83–88.

13. Khan, A. U., Gilani, A. H. 2006 (Dec). „Selective bronchodilatory effect of Rooibos tea (Aspalathus linearis) and its flavonoid, chrysoeriol“. Eur J Nutr. 45(8):463–469.

14. Usmani, O. S., Belvisi, M. G., Patel, H. J., Crispino, N., Birrell, M. A., Korbonits, M., Korbonits, D., Barnes, P. J. 2005 (Feb). „Theobromine inhibits sensory nerve activation and cough“. FASEB J. 19(2):231–233.

15. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

16. Boskabady, M. H., Javan, H., Sajady, M., Rakhshandeh, H. 2007 Oct. „The possible prophylactic effect of Nigella sativa seed extract in asthmatic patients“. Fundam Clin Pharmacol. 21(5):559–566.

17. Venkatesan, N., Punithavathi, D., Babu, M. 2007. „Protection from acute and chronic lung diseases by curcumin“. Adv Exp Med Biol. 595:379–405.

Chronická obstrukční plicní nemoc (CHOPN)

1. Karl-Christian Bergmann. „Dronabinol—eine mögliche neue Therapieoption bei COPD-Patienten mit pulmonaler Kachexie“. Text prezentován roku 17. března 2005 na konferenci Německé pneumologické společnosti v Berlíně.

2. Tan, W. C., Lo, C., Jong, A., Xing, L., Fitzgerald, M. J., Vollmer, W. M., Buist, S. A., Sin, D. D. 2009 (Apr 14). „Marijuana and chronic obstructive lung disease: a population-based study“. CMAJ 180(8):814–820.

Duševní poruchy (obecně)

Porucha pozornosti bez hyperaktivity (ADD) a porucha pozornosti

s hyperaktivitou (ADHD)

1. Bloom, B., Jones, L. I., Freeman, G. 2013. „Summary health statistics for U.S. children: National Health Interview Survey, 2012“. Vital Health Stat 10(258).

2. Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., Gaillac, V., Ginsberg, Y., Henry, C., Krause, J., Lensing, M. B., Manor, I., Niederhofer, H., Nunes-Filipe, C., Ohlmeier, M. D., Oswald, P., Pallanti, S., Pehlivanidis, A., Ramos-Quiroga, J. A., Rastam, M., Ryffel-Rawak, D., Stes, S., Asherson, P. 2010 (Sep 3). „European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD“. BMC Psychiatry 10:67.

3. Drug Enforcement Administration. Office of Diversion Control. Drug & Chemical Evaluation Section. „Ritalin“. Květen 2013. www.deadiversion.usdoj.gov/drug_chem_info/methylphenidate.pdf

4. Lafenêtre, P., Chaouloff, F., Marsicano, G. 2009 (Dec). „Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system“. Neuropharmacology 57(7-8):715–721.

5. Castelli, M., Federici, M., Rossi, S., De Chiara, V., Napolitano, F., Studer, V., Motta, C., Sacchetti, L., Romano, R., Musella, A., Bernardi, G., Siracusano, A., Gu, H. H., Mercuri, N. B., Usiello, A., Centonze, D. 2011 (Nov). „Loss of striatal cannabinoid CB1 receptor function in attention-deficit/hyperactivity disorder mice with point-mutation of the dopamine transporter“. Eur J Neurosci. 34(9):1369–1377.

6. Gururajan, A., Taylor, D. A., Malone, DT. 2012 (Oct). „Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats“. J Psychopharmacol. 26(10):1317–1332.

7. Strohbeck-Kuehner, Peter, Skopp, Gisela, Mattern, Rainer. 2008. „Case report: Cannabis improves symptoms of ADHD“. Cannabinoids 3(1):1–3.

8. Loflin, M., Earleywine, M., De Leo, J., et al. 2013. Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use“. Subst Use Misuse. 49(4):427–434.

9. Ly, C., Gehricke, J. G. 2013 (Dec 30). „Marijuana use is associated with inattention in men and sleep quality in women with attention-deficit/hyperactivity disorder: A preliminary study“. Psychiatry Res. 210(3):1310–1312.

10. Posner, Michael I., Rothbart, Mary K. 2009 (Jun 1). „Toward a physical basis of attention and self regulation“. Phys Life Rev. 6(2):103–120.

Klingberg, T., Forssberg, H., Westerberg, H. 2002 (Sep). „Training of working memory in children with ADHD“. J Clin Exp Neuropsychol. 24(6):781–791.

11. Sykes, D. H., Douglas, V. I., Morgenstern, G. 1973 (Sep). „Sustained attention in hyperactive children“. J Child Psychol Psychiatry 14(3):213–220.

12. Tang, Y. Y., Ma, Y., Wang, J., Fan, Y., Feng, S., Lu, Q., Yu, Q., Sui, D., Rothbart, M. K., Fan, M., Posner, M. I. 2007 (Oct 23). „Short-term meditation training improves attention and self-regulation“. Proc Natl Acad Sci USA 104(43):17152–17156.

Úzkost

1. Kessler, Ronald C., Ph.D., Wai Tat Chiu, AM, Olga Demler, M.A., M.S., Ellen E. Walters, M.S. 2005 (Jun). „Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication“. Arch Gen Psychiatry 62(6):617–627.

2. Witkin, J. M., Tzavara, E. T., Nomikos, G. G. 2005 (Sep). „A role for cannabinoid CB1 receptors in mood and anxiety disorders“. Behav Pharmacol. 16(5-6):315–331.

3. Wen Jiang, Yun Zhang, Lan Xiao, Jamie Van Cleemput, Shao-Ping Ji, Guang Bai, Xia Zhang. 2005. „Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects“. J Clin Invest. 115(11):3104–3116.

4. Corless, I. B., Lindgren, T., Holzemer, W., Robinson, L., Moezzi, S., Kirksey, K., Coleman, C., Tsai, Y. F., Sanzero, Eller L., Hamilton, M. J., Sefcik, E. F., Canaval, G. E., Rivero Mendez, M., Kemppainen, J. K., Bunch, E. H., Nicholas, P. K., Nokes, K. M., Dole, P., Reynolds, N. 2009 (May). „Marijuana effectiveness as an HIV self-care strategy“. Clin Nurs Res. 18(2):172–193.

5. José Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime E. C. Hallak. 2010 (May). „Therapeutical use of the cannabinoids in psychiatry“. Revista Brasileira de Psiquiatria 32(Suppl I).

Autismus

1. „Graph by Autism Speaks“. Dostupné 16. dubna 2015. www.autismspeaks.org/docs/Prevalence_Graph_12_18_2009.pdf

2. Lovaas, O. I. 1987 (Feb). „Behavioral treatment and normal educational and intellectual functioning in young autistic children“. Consult Clin Psychol. 55(1):3–9.

3. Cohen, Howard, Amerine-Dickens, Mila, Smith, Tristram. 2006. „Early intensive behavioral treatment: Replication of the UCLA Model in a community setting“. Journal of Developmental & Behavioral Pediatrics 27(2):145–155.

Sallows, Glen O., Graupner, Tamlynn D. 2005. „Intensive behavioral treatment for children with autism: Four-year outcome and predictors“. American Journal on Mental Retardation 110(6):417–438.

Myers, S. M., Johnson, C. P. 2007 (Nov). „Management of children with autism spectrum disorders“. Pediatrics 120(5):1162–1182.

4. Tamtéž.

5. Ganz, M. L., M.S., Ph.D. 2007. „The lifetime distribution of the incremental societal costs of autism“. Arch Pediatr Adolesc Med. 161(4):343–349.

6. Autism Research Institute, 4182 Adams Ave., San Diego, CA 92116. „Medical Marijuana: A Valuable Treatment for Autism?“ 2003. Autism Research Review International 17(1):3.

7. Treffert, Darold A. 2009 (May 27). „Extraordinary people: Understanding savant syndrome“. Philos Trans R Soc Lond B Biol Sci. 364(1522):1351–1357.

8. Derek Paravicini (narozený v červenci 1979) dokáže po jediném poslechu zahrát jakoukoli skladbu.

9. Richard Wawro (narozený v dubnu 1952) kreslí po paměti na základě jediného pohledu fenomenální, nesmírně podrobné a živé krajinné a mořské scenérie.

10. Daniel Tammet (narozený v lednu 1979) proslul pronikavou a komplexní schopností vidět kladná celá čísla až do 10 000; každému přiřazuje jedinečný tvar, barvu, strukturu a hmatový vjem.

11. Temple Grandinová (narozená v srpnu 1947) je americká doktorka zoologie a profesorka Coloradské státní univerzity.

12. Howlin, P., Goode, S., Hutton, J., Rutter, M. 2009 (May 27). „Savant skills in autism: Psychometric approaches and parental reports“. Philos Trans R Soc Lond B Biol Sci. 364(1522):1359–1367.

Deprese

1. Světová zdravotnická organizace (WHO). 2012. „Mental Health“. „Depression“. Dostupné 16. dubna 2015. www.who.int/mediacentre/factsheets/fs369/en/

2. Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., Shepard, K. V. 1995. „Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS“. Journal of Pain and Symptom Management 10(2):89–97.

3. Neff, G. W., O’Brien, C. B., Reddy, K. R., Bergasa, N. V., Regev, A., Molina, E., Amaro, R., Rodriguez, M. J., Chase, V., Jeffers, L., Schiff, E. 2002 (Aug). „Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease“. Am J Gastroenterol. 97(8):2117–2119.

4. Wen Jiang, Yun Zhang, Lan Xiao, Jamie Van Cleemput, Shao-Ping Ji, Guang Bai, Xia Zhang. 2005. „Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects“. J Clin Invest. 115(11):3104–3116.

5. McLaughlin, R. J., Hill, M. N., Morrish, A. C., Gorzalka, B. B. 2007 (Sep). „Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect“. Behav Pharmacol. 18(5-6):431–438.

6. Bambico, F. R., Katz, N., Debonnel, G., Gobbi, G. 2007. „Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex“. J Neurosci. 27(43):11700–11711.

7. Corless, I. B., Lindgren, T., Holzemer, W., Robinson, L., Moezzi, S., Kirksey, K., Coleman, C., Tsai, Y. F., Sanzero, Eller L., Hamilton, M. J., Sefcik, E. F., Canaval, G. E., Rivero Mendez, M., Kemppainen, J. K., Bunch, E. H., Nicholas, P. K., Nokes, K. M., Dole, P., Reynolds, N. 2009 (May). „Marijuana effectiveness as an HIV self-care strategy“. Clin Nurs Res. 18(2):172–193.

8. Crippa, J. A., Zuardi, A. W., Hallak, J. E. 2010 (May). „Therapeutical use of the cannabinoids in psychiatry“. Rev Bras Psiquiatr. 32 Suppl 1:S56–66.

9. El-Alfy, Abir T., Kelly Ivey, Keisha Robinson, Safwat Ahmed, Mohamed Radwan, Desmond Slade, Ikhlas Khan, Mahmoud ElSohly, Samir Ross. 2010 (Jun). „Antidepressant-like effect of Δ⁹-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L“. Pharmacology Biochemistry and Behavior 95(4):434–442.

10. Michalaka, Johannes, Rohdeb, Katharina, Trojec, Nikolaus F. 2015 (Mar). „How we walk affects what we remember: Gait modifications through biofeedback change negative affective memory bias“. Journal of Behavior Therapy and Experimental Psychiatry 46:121–125.

11. Bruinsma, K, Taren, D. L. 1999 (Oct). „Chocolate: Food or drug?“ J Am Diet Assoc. 99(10):1249–1256.

12. Dhingra, D., Sharma, A. 2006 (Spring). „Antidepressant-like activity of n-hexane extract of nutmeg (Myristica fragrans) seeds in mice“. J Med Food. 9(1):84–89.

Bipolární afektivní porucha (maniodepresivní psychóza)

1. Leverich, Gabriele S., Post, Robert M. 2006 (Apr 1). „Course of bipolar illness after history of childhood trauma“. The Lancet 367(9516):1040–1042.

2. Baldessarini, R. J., Tondo, L., Davis, P., Pompili, M., Goodwin, F. K., Hennen, J. 2006 (Oct). „Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review“. Bipolar Disord. 8(5 Pt 2):625–639.

3. El-Alfy, Abir T., Kelly Ivey, Keisha Robinson, Safwat Ahmed, Mohamed Radwan, Desmond Slade, Ikhlas Khan, Mahmoud ElSohly, Samir Ross. 2010 (Jun). „Antidepressant-like effect of Δ⁹-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L“. Pharmacology Biochemistry and Behavior 95(4):434–442.

4. Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., Hallak, J. 2010 (Jan). „Cannabidiol was ineffective for manic episode of bipolar affective disorder“. J Psychopharmacol. 24(1):135–137.

5. El-Mallakh, R. S., Brown, C. 2007. „The effect of extreme marijuana use on the long-term course of bipolar I illness: A single case study“. J Psychoactive Drugs 39(2):201–202.

6. Ashton, C. H., Moore, P. B., Gallagher, P., Young, A. H. 2005 (May). „Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential“. J Psychopharmacol. 19(3):293–300.

7. Grinspoon, L., Bakalar, J. B. 1998 (Apr-Jun). „The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research“. J Psychoactive Drugs 30(2):171–177.

Posttraumatická stresová porucha (PTSD)

1. Shin, L. M., Rauch, S. L., Pitman, R. K. 2006 (Jul). „Amygdala, medial prefrontal cortex, and hippocampal function in PTSD“. Ann N Y Acad Sci. 1071:67–79.

2. Ganon-Elazar, E., Akirav, I. 2009 (Sep 9). „Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance“. J Neurosci. 29(36):11078–11088.

3. Tamtéž.

4. Fraser, G. A. 2009 (Winter). „The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)“. CNS Neurosci Ther. 15(1):84–88.

5. Harloe, J. P., Thorpe, A. J., Lichtman, A. H. 2008 (Oct 28). „Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks“. Learn Mem. 15(11):806–809.

6. Wang, S., Mason, J. 1999. „Elevations of serum T3 levels and their association with symptoms in World War II veterans with combat-related posttraumatic stress disorder: Replication of findings in Vietnam combat veterans“. Psychosom Med 61:131–138.

7. Redondo, Roger L., Joshua Kim, Autumn L. Arons, Steve Ramirez, Xu Liu, Susumu Tonegawa. 2014 (Sep 18). „Bidirectional switch of the valence associated with a hippocampal contextual memory engram“. Nature 513(7518):426–430. doi:10.1038/nature13725.

Schizofrenie

1. Extrapyramidový systém je oblast mozku, která se podílí na reflexech, pohybu a určování polohy. Stojí mimo normální pyramidové dráhy zodpovědné za pohyb, které vedou z mozku do míchy.

2. Picchioni, Marco M., Murray, Robin M. 2007 (July 14). „Schizophrenia“. BMJ 335(7610):91–95.

3. Tamtéž.

4. Tamtéž.

5. Tamtéž.

6. Tamtéž.

7. Read, J., van Os, J., Morrison, A. P., Ross, C. A. 2005 (Nov). „Childhood trauma, psychosis and schizophrenia: A literature review with theoretical and clinical implications“. Acta Psychiatr Scand. 112(5):330–350.

8. Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkotter, J., Piomelli, D. 2004 (Nov). „Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms“. Neuropsychopharmacology 29(11):2108–2114.

9. Valinová alela 158. genu pro katechol-O-metyltransferázu (COMT); valin je jednou z aminokyselin.

10. Caspi, A., Moffitt, T. E., Cannon, M., McClay, J. Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., Craig, I. W. 2005 (May 15). „Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction“. Biol Psychiatry. 57(10):1117–1127.

11. Henquet, Cécile, Robin Murray, Don Linszen, Jim van Os. 2005 (Jul). „The environment and schizophrenia: The role of cannabis use“. Schizophr Bull. 31(3):608–612.

12. Leweke, F. M., Koethe, D., Pahlisch, F., Schreiber, D., Gerth, C. W., Nolden, B. M., Klosterkötter, J., Hellmich, M., Piomelli, D. 2009. „S39-02 Antipsychotic effects of cannabidiol“. European Psychiatry 24, Supplement 1:S207.

13. Crippa, J. A., Zuardi, A. W., Hallak, J. E. 2010 (May). „Therapeutical use of the cannabinoids in psychiatry“. Rev Bras Psiquiatr. 32, Supplement 1:S56–66.

14. Parolaro, D., Realini, N., Vigano, D., Guidali, C., Rubino, T. 2010 (Jul). „The endocannabinoid system and psychiatric disorders“. Exp Neurol. 224(1):3–14.

Neurologická onemocnění (obecně)

Konopí a neuroprotekce

2. Hamelink, Carol, Hampson, Aidan, Wink, David A., Eiden, Lee E., Eskay, Robert L. 2005 (Aug). „Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity“. JPET 314(2):780–788.

3. Viscomi, M. T., Oddi, S., Latini, L., Pasquariello, N., Florenzano, F., Bernardi, G., Molinari, M., Maccarrone, M. 2009 (Apr 8). „Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway“. J Neurosci. 29(14):4564–4570.

4. Touriño, C., Zimmer, A., Valverde, O. 2010 (Feb 10). „THC prevents MDMA neurotoxicity in mice“. PLoS One 5(2):e9143.

5. Chauhan, N. B., Sandoval, J. 2007 (Jul). „Amelioration of early cognitive deficits by aged garlic extract in Alzheimer’s transgenic mice“. Phytother Res. 21(7):629–640.

6. Hsieh, C. L., Peng, C. H., Chyau, C. C., Lin, Y. C., Wang, H. E., Peng, R. Y. 2007 (Apr 18). „Low-density lipoprotein, collagen, and thrombin models reveal that Rosmarinus officinalis L. exhibits potent antiglycative effects“. J Agric Food Chem. 55(8):2884–2891.

7. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

8. Natarajan, C., Bright, J. J. 2002 (Jun 15). „Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes“. J Immunol. 168(12):6506–6513.

Závislost na alkoholu/nadměrné pití alkoholu

1. Mikuriya, Tod H., M.D. 1970. „Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism“. Medical Times 98(4):187–191.

2. Mikuriya, Tod H., M.D. 2004. „Cannabis as a substitute for alcohol: A harm-reduction approach“. Journal of Cannabis Therapeutics 4(1).

3. Thanos, P. K., Dimitrakakis, E. S., Rice, O., Gifford, A., Volkow, N. D. 2005 (Nov 7). „Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors“. Behav Brain Res. 164(2):206–213.

4. Vinod, K. Y., Yalamanchili, R., Thanos, P. K., Vadasz, C., Cooper, T. B., Volkow, N. D., Hungund, B. L. 2008 (Aug). „Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice“. Synapse 62(8):574–581.

5. Hamelink, Carol, Hampson, Aidan, Wink, David A., Eiden, Lee E., Eskay, Robert L. 2005 (Aug). „Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity“. JPET 314(2):780–788.

6. Enoch, M. A. 2006 (Dec). „Genetic and environmental influences on the development of alcoholism: Resilience vs. risk“. Ann N Y Acad Sci. 1094:193–201.

Alzheimerova choroba

1. Jiaquan Xu, MD; Kenneth D. Kochanek, M.A.; Sherry L. Murphy, B.S.; Betzaida Tejada-Vera, B.S. 2010 (May 20). „National Vital Statistics Reports. Deaths: Final Data for 2007“. Volume 58, Number 19. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System.

2. Stern, Y. 2006 (Jul-Sep). „Cognitive reserve and Alzheimer disease“. Alzheimer Dis Assoc Disord. 20(3 Suppl 2):S69–74.

3. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., de Ceballos, M. L. 2005 (Feb 23). „Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation“. J Neurosci. 25(8):1904–1913.

4. Tolón, R. M., Núñez, E., Pazos, M. R., Benito, C., Castillo, A. I., Martínez-Orgado, J. A., Romero, J. 2009 (Jun). „The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages“. Brain Res. 5.

5. Bisogno, T., Di Marzo, V. 2008. „The role of the endocannabinoid system in Alzheimer’s disease: Facts and hypotheses“. Curr Pharm Des. 14(23):2299–3305.

6. Passmore, M. J. 2008. „The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation“. Int J Geriatr Psychiatry 23(1):116–117.

7. Tucker, Adrienne M., Stern, Yaakov. 2011. „Cognitive reserve in aging“. Current Alzheimer Research, 8.

8. Chauhan, N. B., Sandoval, J. 2007 (Jul). „Amelioration of early cognitive deficits by aged garlic extract in Alzheimer’s transgenic mice“. Phytother Res. 21(7):629–640.

9. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Aggarwal, B. B., Kumar, A., Bharti, A. C. 2003 (Jan-Feb). „Anticancer potential of curcumin: Preclinical and clinical studies“. Anticancer Research 23(1A):363–398.

10. Sommer, Andrei P., Jan Bieschke, Ralf P. Friedrich, Dan Zhu, Erich E. Wanker, Hans J. Fecht, Derliz Mereles, Werner Hunstein. 2012 (Jan). „670 nm laser light and EGCG complementarily reduce amyloid-β aggregates in human neuroblastoma cells: Basis for treatment of Alzheimer’s disease?“ Photomedicine and Laser Surgery 30(1): 54–60.

Amyotrofická laterální skleróza (ALS neboli Lou Gehrigova choroba)

1. Sejvar, J. J., Holman, R. C., Bresee, J. S., Kochanek, K. D., Schonberger, L. B. 2005. „Amyotrophic lateral sclerosis mortality in the United States, 1979–2001“. Neuroepidemiology 25(3):144–152.

2. Pablo, J., Banack, S. A., Cox, P. A., Johnson, T. E., Papapetropoulos, S., Bradley, W. G., Buck, A., Mash, D. C. 2009 (Oct). „Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease“. Acta Neurol Scand. 120(4):216–225.

3. Horner, R. D., Kamins, K. G., Feussner, J. R., Grambow, S. C., Hoff-Lindquist, J., Harati, Y., Mitsumoto, H., Pascuzzi, R., Spencer, P. S., Tim, R., Howard, D., Smith, T. C., Ryan, M. A., Coffman, C. J., Kasarskis. E. J. 2003 (Sep 23). „Occurrence of amyotrophic lateral sclerosis among Gulf War veterans“. Neurology 61(6):742–749.

4. Haley, R. W. 2003 (Sep 23). „Excess incidence of ALS in young Gulf War veterans“. Neurology 61(6):750–756.

5. Carter, G. T., Abood, M. E., Aggarwal, S. K., Weiss, M. D. 2010 (Aug). „Cannabis and amyotrophic lateral sclerosis: Hypothetical and practical applications, a call for clinical trials“. Am J Hosp Palliat Care 27(5):347–356.

6. Weber, M., Goldman, B., Truniger, S. 2010. „Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial“. J.Neurol.Neurosurg.Psychiatry 81:1135–1140.

7. Carter, G. T., et al. 2010. „Cannabis and amyotrophic lateral sclerosis” (viz pozn. 4).

8. Rossi, S., Bernardi, G., Centonze, D. 2010 (Jul). „The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis“. Exp Neurol. 224(1):92–102.

9. Centonze, D., Finazzi-Agrò, A., Bernardi, G., Maccarrone, M. 2007 (Apr). „The endocannabinoid system in targeting inflammatory neurodegenerative diseases“. Trends Pharmacol Sci. 28(4):180–187.

10. Weydt, P., Hong, S., Witting, A., Möller, T., Stella, N., Kliot, M. 2005 (Sep). „Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival“. Amyotroph Lateral Scler Other Motor Neuron Disord. 6(3):182–184.

11. Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., Carter, G. T. 2004 (Mar-Apr). „Survey of cannabis use in patients with amyotrophic lateral sclerosis“. Am J Hosp Palliat Care 21(2):95–104.

12. Carter, G. T., Rosen, B. S. 2001 (Jul-Aug). „Marijuana in the management of amyotrophic lateral sclerosis“. Am J Hosp Palliat Care 18(4):264–270.

13. Rabkin, Judith G., Ph.D., Glenn J. Wagner, Ph.D., Maura Del Bene, RN, BSN. 2000. „Resilience and distress among amyotrophic lateral sclerosis patients and caregivers“. Psychosomatic Medicine 62:271–279.

Epileptický záchvat (status epilepticus)

1. Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., Stephens, G. J. 2010 (Feb). „Cannabidiol displays anti-epileptiform and antiseizure properties in vitro and in vivo“. J Pharmacol Exp Ther. 332(2):569–577.

2. Romigi, A., Bari, M., Placidi, F., Marciani, M. G., Malaponti, M., Torelli, F., Izzi, F., Prosperetti, C., Zannino, S., Corte, F., Chiaramonte, C., Maccarrone, M. 2010 (May). „Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy“. Epilepsia 51(5):768–772.

3. Falenski, K. W., Carter, D. S., Harrison, A. J., Martin, B. R., Blair, R. E., DeLorenzo, R. J. 2009. „Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus“. Brain Res. 1262:64–72.

4. Rüdiger, Lorenz. „Experiences with THC-treatment in children and adolescents“. Text prezentován 12.–13. září 2003 v Kolíně nad Rýnem na 2. konferenci IACM o kanabinoidech v medicíně.

5. Pelliccia, A., Grassi, G., Romano, A., Crocchialo, P. „Treatment with CBD in oily solution of drug-resistant paediatric epilepsies“. Text představen na Kongresu o konopí a kanabinoidech v nizozemském Leidenu roku 2005. International Association for Cannabis as Medicine.

6. Blumer, D. 1999. „Evidence supporting the temporal lobe epilepsy personality syndrome“. Neurology 53(5 Suppl 2):S9–12.

7. Epstein, Arthur W., M.D., Ervin, Frank, M.D. 1956. „Psychodynamic significance of seizure content in psychomotor epilepsy“. Psychosomatic Medicine 18:43–55.

8. Barker, Wayne, M.D. 1948. „Studies on epilepsy: The petit mal attack as a response within the central nervous system to distress in organism-environment integration“. Psychosomatic Medicine 10:73–94.

9. Kemph, J. P., M.D., Zegans, L. S., M.D., Kooi, K. A., M.D., Waggoner, R. W., M.D. 1963. „The emotionally disturbed child with a convulsive disorder“. Psychosomatic Medicine 25:441–449.

10. Strauss, Hans, M.D. 1944. „The effect of mental activity on the incidence of seizures and the electroencephalographic pattern in some epileptics“. Psychosomatic Medicine 6:141–145.

11. Daly, David D., M.D., Barry, Maurice J., Jr., M.D. 1957. „Musicogenic epilepsy: Report of three cases“. Psychosomatic Medicine 19:399–408.

Huntingtonova choroba

1. Lanska, D. J., Lavine, L., Lanska, M. J., Schoenberg, B. S. 1988 (May). „Huntington’s disease mortality in the United States“. Neurology 38(5):769–772.

2. Sandyk, Reuven, Paul Consroe, Lawrence Z. Stern, Stuart R. Snider, Tucson, AZ. 1986 (Apr). „Effects of cannabidiol in Huntington’s disease“. Neurology 36 (Suppl 1):342.

3. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K. 1991 (Nov). „Controlled clinical trial of cannabidiol in Huntington’s disease“. Pharmacol Biochem Behav. 40(3):701–708.

4. Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., Fernández-Ruiz, J. 2007 (Aug). „Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors“. Eur J Neurosci. 26(4):843–851.

5. Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., Fernández-Ruiz, J. 2011 (Sep). „Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease“. J Neurosci Res. 89(9):1509–1518.

6. Fernández-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C., Gómez-Cañas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzmán, M., Mechoulam, R., Ramos, J. A. 2011 (Aug). „Prospects for cannabinoid therapies in basal ganglia disorders“. Br J Pharmacol. 163(7):1365–1378.

Roztroušená skleróza (RS)

1. Elovaara, Irina, M.D., Ph.D.; Maritta Ukkonen, M.D.; Minna Leppakynnas, M.D.; Terho Lehtimaki, M.D., Ph.D.; Mari Luomala, MSc.; Jukka Peltola, M.D.; Prasun Dastidar, M.D. 2000. „Adhesion molecules in multiple sclerosis—Relation to subtypes of disease and methylprednisolone therapy“. Arch Neurol. 57:546–551.

2. Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J., Guaza, C. 2009 (Feb). „A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules“. Mol Cell Neurosci. 40(2):258–266.

3. Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., Inghilleri, M. 2009 (Jan-Feb). „Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo-controlled, crossover study“. Clin Neuropharmacol. 32(1):41–47.

4. Conte, A., Bettolo, C. M., Onesti, E., Frasca, V., Iacovelli, E., Gilio, F., Giacomelli, E., Gabriele, M., Aragona, M., Tomassini, V., Pantano, P., Pozzilli, C., Inghilleri, M. 2009 (May). „Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis“. Eur J Pain. 13(5):472–477.

5. Di Filippo, M., Pini, L. A., Pelliccioli, G. P., Calabresi, P., Sarchielli, P. 2008 (Nov). „Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis“. J Neurol Neurosurg Psychiatry 79(11):1224–1229.

6. Deutsch, S. I., Rosse, R. B., Connor, J. M., Burket, J. A., Murphy, M. E., Fox, F. J. 2008 (May). „Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol“. Spectr. 13(5):393–403.

7. Rog, D. J., Nurmikko, T. J., Young, C. A. 2007 (Sep). „Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial“. Clin Ther. 29(9):2068–2079.

8. Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S.: Sativex Spasticity in MS Study Group. 2007 (Mar). „Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis“. Eur J Neurol. 14(3):290–296.

9. Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., Martino, G., Maccarrone, M. 2007 (Oct). „The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis“. Brain 130(Pt 10):2543–2553.

10. Pryce, G., Baker, D. 2007. „Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors“. British Journal of Pharmacology 150:519–525.

11. Lu, Dai, Kiran Vemuri, V., Duclos, Richard I., Jr., Makriyannis, Alexandros. 2006 (Jul). „The cannabinergic system as a target for anti-inflammatory therapies“. Current Topics in Medicinal Chemistry 6(13):1401–1426(26). Bentham Science Publishers.

12. Freeman, R. M., Adekanmi, O., Waterfield, M. R., Waterfield, A. E., Wright, D., Zajicek, J. 2006 (Nov). „The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo-controlled trial (CAMS-LUTS)“. Int Urogynecol J Pelvic Floor Dysfunct. 17(6):636–641.

13. Barnes, M. P. 2006 (Apr). „Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain“. Expert Opin Pharmacother. 7(5):607–615.

14. Yang, C., Hader, W., Zhang, X. 2006 (Mar 3). „Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite“. Brain Res. 1076(1): 238–242.

15. Trebst, C., Stangel, M. 2005 (Aug). „Cannabinoids in multiple sclerosis—therapeutically reasonable?“ Fortschr Neurol Psychiatr. 73(8):463–469.

16. Rog, D. J., Nurmikko, T. J., Friede, T., Young, C. A. 2005 (Sep 27). „Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis“. Neurology 65(6):812–819.

17. Perras, C. 2005 (Sep). „Sativex for the management of multiple sclerosis symptoms“. Issues Emerg Health Technol. 72:1–4.

18. Rog, D. J., et al. 2005. „Randomized, controlled trial...“. Viz pozn. 16.

19. Wade, D. T., Makela, P., Robson, P., House, H., Bateman, C. 2004 (Aug). „Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients“. Mult Scler. 10(4):434–441.

20. Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., Fowler, C. J. 2004. „An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis“. Multiple Sclerosis 10(4):425–433.

21. Page, S. A., Verhoef, M. J., Stebbins, R. A., Metz, L. M., Levy, J. C. 2003. „Cannabis use as described by people with multiple sclerosis“. Can J Neurol Sci 30(3):201–205.

22. Consroe, P., Musty, R., Rein, J., Tillery, W., Pertwee, R. 1997. „The perceived effects of smoked cannabis on patients with multiple sclerosis“. European Neurology 38(1):44–48.

23. Martyn, C. N., Illis, L. S., Thom, J. 1995. „Nabilone in the treatment of multiple sclerosis“. Lancet 345(8949):579.

24. Greenberg, H. S., Werness, S. A. S., Pugh, J. E., Andrus, R. O., Anderson, D. J., Domino, E. F. 1994. „Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers“. Clinical Pharmacology and Therapeutics 55:324–328.

25. Meinck, H. M., Schönle, P. W., Conrad, B. 1989. „Effect of cannabinoids on spasticity and ataxia in multiple sclerosis“. Journal of Neurology 236(2):120–122.

26. Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., Myers, L. W. 1987. „Delta-9-THC in the treatment of spasticity associated with multiple sclerosis“. Advances in Alcohol and Substance Abuse 7(1):39–50.

27. Petro, D. J., Ellenberger, C., Jr. 1981. „Treatment of human spasticity with delta 9-tetrahydrocannabinol“. Journal of Clinical Pharmacology 21(8-9 Suppl):413S–416S.

28. Varda Mei-Tal, M.D., Sanford Meyerowitz, M.D., George L. Engel, M.D. 1970. „The role of psychological process in a somatic disorder: Multiple sclerosis“. Psychosomatic Medicine 32:67–86.

29. Kurt D. Ackerman, M.D., Ph.D., Rock Heyman, M.D., Bruce S. Rabin, M.D., Ph.D., Barbara P. Anderson, Ph.D., Patricia R. Houck, MSH, Ellen Frank, Ph.D., Andrew Baum, Ph.D. 2002. „Stressful life events precede exacerbations of multiple sclerosis“. Psychosomatic Medicine 64:916–920.

G. S. Philippopoulos, M.D., E. D. Wittkower, M.D., A. Cousineaum, M.A. 1958. „The etiologic significance of emotional factors in onset and exacerbations of multiple sclerosis“. Psychosomatic Medicine 20:458–474.

30. Natarajan, C., Bright, J. J. 2002 (Jun 15). „Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes“. J Immunol. 168(12):6506–6513.

31. Sundqvist, E., Bäärnhielm, M., Alfredsson, L., Hillert, J., Olsson, T., Kockum, I. 2010 (Dec). „Confirmation of association between multiple sclerosis and CYP27B1“. Eur J Hum Genet. 18(12):1349–1352.

Parkinsonova choroba

2. Venderová, K., Růžička, E., Voříšek, V., Višňovský, P. 2004. „Survey on cannabis use in Parkinson’s disease: Subjective improvement of motor symptoms“. Movement Disorders 19(9):1102–1106.

3. Farooq, M. U., Ducommun, E., Goudreau, J. 2009 (Mar). „Treatment of a hyperkinetic movement disorder during pregnancy with Dronabinol“. Parkinsonism Relat Disord. 15(3):249–251.

4. Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., Steardo, L. 2009 (Winter). „Cannabidiol: A promising drug for neurodegenerative disorders?“ CNS Neurosci Ther. 15(1):65–75.

5. Aggarwal, B. B., Kumar, A., Bharti, A. C. 2003 (Jan-Feb). „Anticancer potential of curcumin: Preclinical and clinical studies“. Anticancer Research 23(1A):363–398.

Tourettův syndrom

1. Moss, D. E., Manderscheid, P. Z, Montgomery, S. P., Norman, A. B., Sanberg, P. R. 1989. „Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders“. Life Sci. 44(21):1521–1525.

2. Müller-Vahl, K. R., Kolbe, H., Schneider, U., Emrich, H. M. 1998 (Dec). „Cannabinoids: Possible role in pathophysiology and therapy of Gilles de la Tourette syndrome“. Acta Psychiatr Scand. 98(6):502–506.

3. Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., Emrich, H. M. 2002 (Mar). „Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial“. Pharmacopsychiatry 35(2):57–61.

Müller-Vahl, K. R., Koblenz, A., Jöbges, M., Kolbe, H., Emrich, H. M., Schneider, U. 2001 (Jan). „Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological per-

formance“. Pharmacopsychiatry 34(1):19–24.

Müller-Vahl, K. R., Prevedel, H., Theloe, K., Kolbe, H., Emrich, H. M., Schneider, U. 2003 (Feb). „Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): No influence on neuropsychological performance“. Neuropsychopharmacology 28(2):384–388.

Curtis, A., Clarke, C. E., Rickards, H. E. 2009 (Oct 7). „Cannabinoids for Tourette’s Syndrome“. Cochrane Database Syst Rev. (4):CD006565.

4. Hasan, A., Rothenberger, A., Münchau, A., Wobrock, T., Falkai, P., Roessner, V. 2010 (Apr). „Oral delta-9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report“. J Clin Psychopharmacol. 30(2):190–192.

5. Curtis, A., Clarke, C. E., Rickards, H. E. 2009 (Oct 7). „Cannabinoids for Tourette’s Syndrome“. Cochrane Database Syst Rev. (4):CD006565.

6. Müller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., Emrich, H. M. 2003 (Apr). „Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week

randomized trial“. J Clin Psychiatry 64(4):459–465.

7. Müller-Vahl, K. R., Prevedel, H., Theloe, K., Kolbe, H., Emrich, H. M., Schneider, U. 2003 (Feb). „Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): No influence on neuropsychological performance“. Neuropsychopharmacology 28(2):384–388.

8. Müller-Vahl, K. R., et al. 2002. „Treatment of Tourette’s syndrome...“. Viz pozn. 3.

9. Müller-Vahl, K. R., et al. 2001. „Influence of treatment of Tourette syndrome...“. Viz pozn. 3.

10. Schneider, U., Muller-Vahl, K. R., Stuhrmann, M., Gadzicki, D., Heller, D., Seifert, J., Emrich, H. M. 2000 (Oct). „The importance of the endogenous cannabinoid system in various neuropsychiatric disorders“. Fortschr Neurol Psychiatr. 68(10):433–438.

11. Müller-Vahl, K. R., Kolbe, H., Schneider, U., Emrich, H. M. 1999 (Oct). „Cannabis in movement disorders“. Forsch Komplementarmed. 6 Suppl 3:23–27.

12. Müller-Vahl, K. R., et al. 1998. „Cannabinoids: possible role...“. Viz pozn. 2.

13. Moss, D. E., Manderscheid, P. Z., Montgomery, S. P., Norman, A. B., Sanberg, P. R. 1989. „Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders“. Life Sci. 44(21):1521–1525.

Obstetrická péče a gynekologické obtíže neboli OBGYN (obecně)

1. Russo, Ethan, M.D. 2002. „Cannabis treatments in obstetrics and gynecology: A historical review“. Journal of Cannabis Therapeutics 2(3/4):5–35. Také in: Ethan Russo, Melanie Dreher, Mary Lynn Mathre (ed.), Women and Cannabis: Medicine, Science, and Sociology (The Haworth Integrative Healing Press, imprint The Haworth Press, Inc., 2002), s. 5–35.

2. Sam’l O. L. Potter, M.A., M.D., MRCP (Lond.) 1892. A Compend of Materia Medica and Therapeutics and Prescription Writing; with especial references to the physiological actions of drugs (Philadelphia: P. Blakiston, Son & Co.), s. 123. Vychází z díla U.S. Pharmacopeia, 5. vydání.

Potrat, samovolný potrat a plodnost

1. Piomelli, Daniele. 2004. „THC: Moderation during implantation“. Nature Medicine 10:19–20.

Paria, B. C., H. Song, X. Wang, P. C. Schmid, R. J. Krebsbach, H. H. Schmid, T. I. Bonner, A. Zimmer, S. K. Dey. 2001 (Jun 8). „Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation“. J Biol Chem. 276(23):20523–20528.

2. Paria, B. C., Wang, H., Dey, S. K. 2002 (Dec 31). „Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation“. Chem Phys Lipids. 121(1-2):201–210.

Porodní bolesti

1. L. Grinspoon, M.D., James Bakalar. 1997. Marijuana, The Forbidden Medicine (New Haven a Londýn: Yale University Press. Revidované a rozšířené vydání).

Endometrióza

1. Dmitrieva, N., Nagabukuro, H., Resuehr, D., Zhang, G., McAllister, S. L., McGinty, K. A., Mackie, K., Berkley, K. J. 2010 (Dec). „Endocannabinoid involvement in endometriosis“. Pain 151(3):703–710.

2. Leconte, M., Nicco, C., Ngô, C., Arkwright, S., Chéreau, C., Guibourdenche, J., Weill, B., Chapron, C., Dousset, B., Batteux, F. 2010 (Dec). „Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis“. Am J Pathol. 177(6):2963–2970.

3. Heim, C., Ehlert, U., Hanker, J. P., Hellhammer, H. H. 1998 (May 1). „Abuse-related posttraumatic stress disorder and alteration of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain“. Psychosomatic Medicine 60:302–318.

Menstruační bolesti

1. Grotenhermen, F., Schnelle, M. 2003. „Survey on the medical use of cannabis and THC in Germany“. J Cannabis Ther 3(2):17–40.

2. Kassi, E., Papoutsi, Z., Fokialakis, N., Messari, I., Mitakou, S., Moutsatsou, P. 2004 (Nov 17). „Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties“. J Agric Food Chem. 52(23):6956–6961.

3. Modaress Nejad, V., Asadipour, M. 2006 (May-Jul). „Comparison of the effectiveness of fennel and mefenamic acid on pain intensity in dysmenorrhoea“. East Mediterr Health J. 12(3-4):423–427.

Ranní nevolnost

1. Westfall, R. E., Janssen, P. A., Lucas, P., Capler, R. 2006. „Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’“. Complement Ther Clin Pract 12(1):27–33.

Těhotenství

1, El-Talatini, M. R., Taylor, A. H., Konje, J. C. 2010 (Apr). „The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle“. Fertil Steril. 93(6):1989–1996.

2. Greenland, S., Richwald, G. A., Honda, G. D. 1983 (Jun). „The effects of marijuana use during pregnancy. II. A study in a low-risk home-delivery population“. Drug Alcohol Depend. 11(3-4):359–366.

Osteoporóza

1. Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., Essig, J., Erxlebe, E., Bab, I., Kubisch, C., de Vernejoul, M. C., Zimmer, A. 2005 (Nov 15). „Cannabinoid receptor type 2 gene is associated with human osteoporosis“. Hum Mol Genet. 14(22):3389–3396.

2. Orr Ofek, Meliha Karsak, Nathalie Leclerc, Meirav Fogel, Baruch Frenkel, Karen Wright, Joseph Tam, Malka Attar-Namdar, Vardit Kram, Esther Shohami, Raphael Mechoulam, Andreas Zimmer, Itai Bab. 2006 (Jan 17). „Peripheral cannabinoid receptor, CB2, regulates bone mass“. PNAS 103(3):696–701.

3. Bab, I., Zimmer, A., Melamed, E. 2009. „Cannabinoids and the skeleton: From marijuana to reversal of bone loss“. Ann Med. 41(8):560–567.

Bolest (obecně)

1. Lee, W. M. 2004 (Jul). „Acetaminophen and the U.S. Acute Liver Failure Study Group: Lowering the risks of hepatic failure“. Hepatology 40(1):6–9.

2. Green, G. A. 2001. „Understanding NSAIDs: From aspirin to COX-2“. Clin Cornerstone 3(5):50–60.

3. Wolfe, Sidney M., M.D., Larry D. Sasich, Pharm.D., MPH, Rose-Ellen Hope, RPh, Public Citizen’s Health Research Group. 1999. Worst Pills, Best Pills—A Consumer’s Guide to Avoiding Drug-Induced Death or Illness (New York: Pocket Books).

4. Moore, T. J., Cohen, M. R., Furberg, C. D. 2007 (Sep 10). „Serious adverse drug events reported to the Food and Drug Administration, 1998-2005“. Arch Intern Med. 167(16):1752–1759.

5. Ethan B. Russo, M.D. „The Role of Cannabis and Cannabinoids in Pain Management“. In: Richard S. Weiner, Ph.D. (ed.), Pain Management: A Practical Guide for Clinicians (Londýn, New York, Washington, D.C.: CRC Press, 2002), kap. 31.

6. Conte, A., Bettolo, C. M., Onesti, E., Frasca, V., Iacovelli, E., Gilio, F., Giacomelli, E., Gabriele, M., Aragona, M., Tomassini, V., Pantano, P., Pozzilli, C., Inghilleri, M. 2009 (May). „Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis“. Eur J Pain 13(5):472–477.

7. Welch, S. P., Eads, M. 1999 (Nov 27). „Synergistic interactions of endogenous opioids and cannabinoid systems“. Brain Res. 848(1-2):183–190.

8. Burstein, Sumner H., Zurier, Robert B. 2009 (Mar). „Cannabinoids, endocannabinoids, and related analogs in inflammation“. AAPS J. 11(1):109–119.

9. Wallace, M., Schulteis, G., Atkinson, J. H., Wolfson, T., Lazzaretto, D., Bentley, H., Gouaux, B., Abramson, I. 2007 (Nov). „Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers“. Anesthesiology 107(5):785–796.

Kraft, B., Frickey, N. A., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., Kress, H. G. 2008 (Jul). „Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers“. Anesthesiology 109(1):101–110.

10. Ethan B. Russo, M.D. „The Role of Cannabis and Cannabinoids...“. Viz pozn. 5.

11. Burstein a Zurier. 2009. „Cannabinoids...“. Viz pozn. 8.

12. Conte, A., et al. 2009. „Cannabinoid-induced effects...“. Viz pozn. 6.

13. Wallace, M., et al. 2007. „Dose-dependent effects of smoked cannabis...“. Viz pozn. 9.

14. Heinrich, U., Neukam, K., Tronnier, H., Sies, H., Stahl, W. 2006 (Jun). „Long-term ingestion of high-flavanol cocoa provides photoprotection against UV-induced erythema and improves skin condition in women“. J Nutr. 136(6):1565–1569.

15. Gagnier, J. J., van Tulder, M. W., Berman, B., Bombardier, C. 2007 (Jan 1). „Herbal medicine for low back pain: A Cochrane review“. Spine 32(1):82–92.

16. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

18. Beltran, J., Ghosh, A. K., Basu, S. 2007 (Mar 1). „Immunotherapy of tumors with neuroimmune ligand capsaicin“. J Immunol. 178(5):3260–3264.

19. Elwakeel, H. A., Moneim, H. A., Farid, M., Gohar, A. A. 2007 (Jul). „Clove oil cream: A new effective treatment for chronic anal fissure“. Colorectal Dis. 9(6):549–552.

20. Chaieb, K., Hajlaoui, H., Zmantar, T., Kahla-Nakbi, A. B., Rouabhia, M., Mahdouani, K., Bakhrouf, A. 2007 (Jun). „The chemical composition and biological activity of clove essential oil, Eugenia caryophyllata (Syzigium aromaticum L. Myrtaceae): A short review“. Phytother Res. 21(6):501–506.

22. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Viz pozn. 17.

23. Modaress, Nejad, V., Asadipour, M. 2006 (May-Jul). „Comparison of the effectiveness of fennel and mefenamic acid on pain intensity in dysmenorrhoea“. East Mediterr Health J. 12(3-4):423–427.

24. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Viz pozn. 16.

25. Ojewole, J. A. 2006 (Sep). „Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats“. Phytother Res. 20(9):764–772.

26. Umukoro, S., Ashorobi, R. B. 2008 (Feb 12). „Further pharmacological studies on aqueous seed extract of Aframomum melegueta in rats“. J Ethnopharmacol. 115(3):489–493.

27. Umukoro, S., Ashorobi, R. B. 2007 (Feb 12). „Further studies on the antinociceptive action of aqueous seed extract of Aframomum melegueta“. J Ethnopharmacol. 109(3):501–504.

28. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Viz pozn. 17.

29. Nomicos, E. Y. 2007 (Nov-Dec). „Myrrh: medical marvel or myth of the magi?“ Holist Nurs Pract. 21(6):308–323.

30. Cemek, M., Enginar, H., Karaca, T., Unak, P. 2006 (Nov-Dec). „In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats“. Photochem Photobiol. 82(6):1691–1696.

31. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Viz pozn. 16.

Chronické nemaligní bolesti

1. Wolff, R., Clar, C., Lerch, C., Kleijnen, J. 2011 (Feb). „Epidemiology of chronic non-malignant pain in Germany“. Schmerz. 25(1):26–44.

2. Bujalska, M. 2008. „Effect of cannabinoid receptor agonists on Streptozotocin-induced hyperalgesia in diabetic neuropathy“. Pharmacology 82(3):193–200.

3. Haroutiunian, S., Rosen, G., Shouval, R., Davidson, E. 2008. „Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain“. J Pain Palliat Care Pharmacother. 22(3):213–217.

Migréna

1. Zebenholzer, K., Rudel, E., Frantal, S., Brannath, W., Schmidt, K., Wöber-Bingöl, C., Wöber, C. 2011 (Mar). „Migraine and weather: A prospective diary-based analysis“. Cephalalgia 31(4):391–400.

2. Wöber, C., Brannath, W., Schmidt, K., Kapitan, M., Rudel, E., Wessely, P., Wöber-Bingöl, Ç. 2007. „Prospective analysis of factors related to migraine attacks: The PAMINA study“. Cephalalgia 27(4):304–314.

3. Lay, C. L., Broner, S. W. 2009 (May). „Migraine in women“. Neurologic Clinics 27(2):503–511.

4. Etminan, M., Takkouche, B., Isorna, F. C., Samii, A. 2005 (Jan 8). „Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies“. BMJ 330(7482):63.

5. Russo, Ethan B., M.D. 2001. „Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment“. Journal of Cannabis Therapeutics 1(2).

Russo, Ethan, M.D. 1998. „Cannabis for migraine treatment: The once and future prescription? An historical and scientific review“. Pain 76:3–8.

6. Russo, Ethan B., M.D. 2004 (Feb-Apr). „Clinical Endocannabinoid Deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?“ Neuroendocrinology Letters 25(1/2).

7. Raby, W. N., Modica, P. A., Wolintz, R. J., Murtaugh, K. 2006 (Feb). „Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: A case report“. J Ocul Pharmacol Ther. 22(1):68–75.

8. Volfe, Z., Dvilansky, A., Nathan, I. 1985. „Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients“. Int J Clin Pharm. Res V(4):243–246.

9. Kozersky, S., Dewey, W. L., Harris, L. S. 1973. „Antipyretic analgesic and anti-inflammatory effects of delta-9-THC in the rat“. Europ. J. Pharmacol. 24:1.

10. Adams, M. D., Earnhardt, J. T., Dewey, W. L., Harris, L. S. 1976. „Vasoconstrictor actions of delta-8 and delta-9-THC in the rat“. J. Pharmacol. Exp. Therap. 196:649.

11. Mikuriya, T. H. 1969. „Marijuana in medicine: Past, present and future“. Calif. Med. 110:34–40.

12. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (Jul 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

13. Wöber, C., Brannath, W., Schmidt, K., Kapitan, M., Rudel, E., Wessely, P., Wöber-Bingöl, Ç. 2007. „Prospective analysis of factors related to migraine attacks: The PAMINA study“. Cephalalgia 27(4):304–314.

14. Evans, R. W., M.D., Couch, J. R., M.D., Ph.D. 2001. „Orgasm and migraine“. Headache 41:512–514.

15. Couch, J., Bearss, C. 1990. „Relief of migraine with sexual intercourse“. Headache 30:302.

Neuropatie (obecně)

1. Burstein, Sumner H., Zurier, Robert B. 2009 (Mar). „Cannabinoids, endocannabinoids, and related analogs in inflammation“. AAPS J. 11(1):109–119.

2. Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., Fishman, S. 2008 (Jun). „A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain“. J Pain 9(6):506–521.

3. Attal, N., Brasseur, L., Guirimand, D., Clermond-Gnamien, S., Atlami, S., Bouhassira, D. 2004 (Apr). „Are oral cannabinoids safe and effective in refractory neuropathic pain?“ Eur J Pain 8(2):173–177.

4. Berman, J. S., Symonds, C., Birch, R. 2004 (Dec). „Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial“. Pain 112(3):299–330.

5. Wade, D. T., Robson, P., House, H., Makela, P., Aram, J. 2003 (Feb). „A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms“. Clin Rehabil. 17(1): 21–29.

6. Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., Schneider, U. 2003 (Oct 1). „Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial“. Journal of the American Medical Association 290(13):1757–1762.

Neuropatie spojené s AIDS

1. Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., Petersen, K. L. 2007 (Feb 13). „Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial“. Neurology 68(7):515–521.

2. Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., Atkinson, J. H. 2009 (Feb). „Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial“. Neuropsychopharmacology 34(3):672–680.

Bolest spojená s pokročilým stádiem rakoviny

1. Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., Fallon, M. T. 2010 (Feb). „Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain“. J Pain Symptom Manage. 39(2):167–179.

Prionová onemocnění (transmisivní spongiformní encefalopatie)

1. Mead, Simon, MRCP, Jerome Whitfield, M.A., Mark Poulter, BSc., Paresh Shah, Ph.D., James Uphill, BSc., Tracy Campbell, BSc., Huda Al-Dujaily, BSc., Holger Hummerich, Ph.D., Jon Beck, BSc., Charles A. Mein, Ph.D., Claudio Verzilli, Ph.D., John Whittaker, Ph.D., Michael P. Alpers, FRS, John Collinge, FRS. 2009. „A novel protective prion protein variant that colocalizes with kuru exposure“. N Engl J Med. 361:2056–2065.

2. Llewelyn, C. A., Hewitt, P. E., Knight, R. S., Amar, K., Cousens, S., Mackenzie, J., Will, R. G. 2004. „Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion“. Lancet 363:417–421.

3. Sevda Dirikoc, Suzette A. Priola, Mathieu Marella, Nicole Zsürger, Joëlle Chabry. 2007 (Sep 5). „Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity“. J Neurosci. 27(36):9537–9544.

4. Spojené státy americké zastoupené Ministerstvem zdravotnictví a sociálních služeb. Patent č. 09/674028, podaný 2. února 2001 (Aidan J. Hampson, Julius Axelrod, Maurizio Grimaldi). Patent 6630507 udělen 7. října 2003. Odhadovaný termín vypršení: 2021. Kanabinoidy jako antioxidanty a neuroprotektanty. www.patentstorm.us/patents/6630507.html

5. Sevda Dirikoc, et al. 2007. „Nonpsychoactive cannabidiol...“. Viz pozn. 3.

6. Během indikovaného období bylo myším třikrát týdně intraperitoneálně aplikováno 200 µl látky (20, nebo 60 mg CBD na kg tělesné hmotnosti ředěných na 0,9 % etanolem, cremoforem a chloridem sodným v poměru 1:1:2). CBD pocházel z GW Pharmaceuticals (Wiltshire, Spojené království), byl rozpuštěn v etanolu na molární koncentraci 10^–2 a před použitím skladován při –20 °C.

Srpkovitá anémie

1. Howard, J., Anie, K. A., Holdcroft, A., Korn, S., Davies, S. C. 2005. „Cannabis use in sickle cell disease: A questionnaire study“. Br J Haematol. 131(1):123–128.

2. Kohli, D. R., Li, Y., Khasabov, S. G., Gupta, P., Kehl, L. J., Ericson, M. E., Nguyen, J., Gupta, V., Hebbel, R. P., Simone, D. A., Gupta, K. 2010 (Jul 22). „Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids“. Blood 116(3):456–465.

3. Shmist, Y. A., Goncharov, I., Eichler, M., Shneyvays, V., Isaac, A., Vogel, Z., Shainberg, A. 2006 (Feb). „Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production“. Mol Cell Biochem 283(1-2):75–83.

4. Levenson, James L., M.D., Donna K. McClish, Ph.D., Bassam A. Dahman, B.S., Viktor E. Bovbjerg, Ph.D., MPH, Vanessa de A. Citero, M.D., Lynne T. Penberthy, M.D., MPH, Imoigele P. Aisiku, M.D., MSCR, John D. Roberts, M.D., Susan D. Roseff, M.D., Wally R. Smith, M.D. 2008. „Depression and anxiety in adults with sickle cell sisease: The PiSCES Project“. Psychosomatic Medicine 70:192–196.

5. Zhang, C., Li, X., Lian, L., Chen, Q., Abdulmalik, O., Vassilev, V., Lai, C. S., Asakura, T. 2004 (Jun). „Anti-sickling effect of MX-1520, a prodrug of vanillin: An in vivo study using rodents“. Br J Haematol. 125(6):788–795.

Kožní choroby (obecně)

1. Bíró, Tamás, Balázs I. Tóth, György Haskó, Ralf Paus, Pál Pacher. 2009 (Aug). „The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities“. Trends Pharmacol Sci. 30(8):411–420.

2. Telek, A., Bíró, T., Bodó, E., Tóth, B. I., Borbíró, I., Kunos, G., Paus, R. 2007 (Nov). „Inhibition of human hair follicle growth by endo- and exocannabinoids“. FASEB J. 21(13):3534–3541.

3. Stander, S., Reinhardt, H. W., Luger, T. A. 2006 (Sep). „Topical cannabinoid agonists: An effective new possibility for treating chronic pruritus“. Hautarzt. 57(9):801–807.

4. Neff, G. W., O’Brien, C. B., Reddy, K. R., Bergasa, N. V., Regev, A., Molina, E., Amaro, R., Rodriguez, M. J., Chase, V., Jeffers, L., Schiff, E. 2002 (Aug). „Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease“. Am J Gastroenterol. 97(8):2117–2119.

5. Yosipovitch, G., Tang, M., Dawn, A. G., Chen, M., Goh, C. L., Huak, Y., Seng, L. F. 2007. „Study of psychological stress, sebum production and acne vulgaris in adolescents“. Acta Derm Venereol. 87(2):135–139.

6. Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., Schmidt, K. 2001 (Sep). „The relationship of depression and stressors to immunological assays: A meta-analytic review“. Brain Behav Immun. 15(3):199–126.

7. Marnewick, J., Joubert, E., Joseph, S., Swanevelder, S., Swart, P., Gelderblom, W. 2005 (Jun 28). „Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas“. Cancer Lett. 224(2):193–202.

8. Heinrich, U., Neukam, K., Tronnier, H., Sies, H., Stahl, W. 2006 (Jun). „Long-term ingestion of high-flavanol cocoa provides photoprotection against UV-induced erythema and improves skin condition in women“. J Nutr. 136(6):1565–1569.

9. Mitani, H., Ryu, A., Suzuki, T., Yamashita, M., Arakane, K., Koide, C. 2007 (Apr-Jun). „Topical application of plant extracts containing xanthine derivatives can prevent UV-induced wrinkle formation in hairless mice“. Photodermatol Photoimmunol Photomed. 23(2-3):86–94.

10. Mondello, F., De Bernardis, F., Girolamo, A., Cassone, A., Salvatore, G. 2006 (Nov 3). „In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil, against azole-susceptible and resistant human pathogenic Candida species“. BMC Infect Dis. 6:158.

11. Ferrini, A. M., Mannoni, V., Aureli, P., Salvatore, G., Piccirilli, E., Ceddia, T., Pontieri, E., Sessa, R., Oliva, B. 2006 (Jul-Sep). „Melaleuca alternifolia essential oil possesses potent anti-staphylococcal activity extended to strains resistant to antibiotics“. Int J Immunopathol Pharmacol. 19(3):539–544.

12. Vazquez, J. A., Zawawi, A. A. 2002 (Sep-Oct). „Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS“. HIV Clin Trials 3(5):379–385.

13. De Lucca, A. J., Bland, J. M., Vigo, C. B., Cushion, M., Selitrennikoff, C. P., Peter, J., Walsh, T. J. 2002 (Apr). „CAY-I, a fungicidal saponin from Capsicum sp. fruit“. Med Mycol. 40(2):131–137.

14. Bergsson, G., Steingrímsson, O., Thormar, H. 1999 (Nov). „In vitro susceptibilities of Neisseria gonorrhoeae to fatty acids and monoglycerides“. Antimicrob Agents Chemother. 43(11):2790–2792.

15. Bergsson, G., Arnfinnsson, J., Steingrímsson, O., Thormar, H. 2001(Oct). „Killing of Gram-positive cocci by fatty acids and monoglycerides“. APMIS. 109(10):670–678.

16. Bergsson, G., Arnfinnsson, J., Steingrímsson, O., Thormar, H. 2001 (Nov). „In vitro killing of Candida albicans by fatty acids and monoglycerides“. Antimicrob Agents Chemother. 45(11):3209–3212.

17. Bergsson, G., Arnfinnsson, J., Karlsson, S. M., Steingrímsson, O., Thormar, H. 1998 (Sep). „In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides“. Antimicrob Agents Chemother. 42(9):2290–2294.

18. Isaacs, C. E., Kim, K. S., Thormar, H. 1994 (Jun 6). „Inactivation of enveloped viruses in human bodily fluids by purified lipids“. Ann N Y Acad Sci. 724:457–464.

19. Tedeschi, P., Maietti, A,. Boggian, M., Vecchiati, G., Brandolini, V. 2007 (Sep). „Fungitoxicity of lyophilized and spray-dried garlic extracts“. J Environ Sci Health B. 42(7):795–799.

20. Umukoro, S., Ashorobi, R. B. 2008 (Feb 12). „Further pharmacological studies on aqueous seed extract of Aframomum melegueta in rats“. J Ethnopharmacol. 115(3):489–493.

21. Tampieri, M. P., Galuppi, R., Macchioni, F., Carelle, M. S., Falcioni, L., Cioni, P. L., Morelli, I. 2005 (Apr). „The inhibition of Candida albicans by selected essential oils and their major components“. Mycopathologia. 159(3):339–345.

22. Fu, Y., Zu, Y., Chen, L., Shi, X., Wang, Z., Sun, S., Efferth, T. 2007 (Oct). „Antimicrobial activity of clove and rosemary essential oils alone and in combination“. Phytother Res. 21(10):989–994.

23. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

24. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B. 2008 (Feb 15). „Curcumin as ‘Curecumin’: From kitchen to clinic“. Biochem Pharmacol. 75(4):787–809.

Akné

2. Yosipovitch, Gil, Mark Tang, Aerlyn G. Dawn, Mark Chen, Chee Leok Goh, Yiong Huak Chan, Lim Fong Seng. 2007 (Mar). „Study of psychological stress, sebum production and Acne vulgaris in adolescents“. Acta Dermato-Venereologica 87(2):135–139.

Dermatitida (ekzém)

2. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (Jul 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

Nežádoucí růst ochlupení (hirsutismus)

2. Fava, G. A., Grandi, S., Savron, G., Bartolucci, G., Santarsiero, G., Trombini, G., Orlandi, C. 1989. „Psychosomatic assessment of hirsute women“. Psychother Psychosom. 51(2):96–100.

3. Javidnia, K., Dastgheib, L., Mohammadi Samani, S., Nasiri, A. 2003. „Antihirsutism activity of fennel (fruits of Foeniculum vulgare) extract. A double-blind placebo controlled study“. Phytomedicine 10(6-7):455–458.

Ztráta vlasů (plešatění)

Svědění (pruritus)

Psoriáza (lupénka)

2. Aggarwal, B. B., Kumar, A., Bharti, A. C. 2003 (Jan-Feb). „Anticancer potential of curcumin: Preclinical and clinical studies“. Anticancer Research 23(1A):363–398.

Seborea

1. Schwartz, R. A., Janusz, C. A., Janniger, C. K. 2006 (Jul 1). „Seborrheic dermatitis: An overview“. Am Fam Physician 74(1):125–130.

Systémová sklerodermie

Zvracení (obecně)

Nevolnost a zvracení vyvolané chemoterapií

1. Parker, L. A., Rock, E., Limebeer, C. 2011 (Aug). „Regulation of nausea and vomiting by cannabinoids“. Br J Pharmacol. 163(7):1411–1422.

2. Pan, H., Mukhopadhyay, P., Rajesh, M., Patel, V., Mukhopadhyay, B., Gao, B., Haskó, G., Pacher, P. 2009 (Mar). „Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death“. J Pharmacol Exp Ther. 328(3):708–714.

3. Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., Baranowski, V. 2007. „Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting“. Curr Med Res Opin. 23(3):533–543.

4. Walsh, D., Nelson, K. A., Mahmoud, F. A. 2003 (Mar). „Established and potential therapeutic applications of cannabinoids in oncology“. Support Care Cancer. 11(3):137–143.

5. Tramèr, Martin R., Dawn Carroll, Fiona A. Campbell, D. John, M. Reynolds, R. Andrew Moore, Henry J. McQuay. 2001. „Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review“. BMJ 323:16–21.

6. Abrahamov, A., Abrahamov, A., Mechoulam, R. 1995. „An efficient new cannabinoid antiemetic in pediatric oncology“. Life Sci. 56(23-24):2097–2102.

7. Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S., Saiers, J. L., Hamm, J., Salva, K., Wiernik, P. H., Holroyde, C. P., Hammill, S., et al. 1991 (Aug). „Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting“. J Pain Symptom Manage. 6(6):352–359.

8. Cunningham, D., Bradley, C. J., Forrest, G. J., et al. 1988. „A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues“. Eur J Cancer Clin Oncol 24:685–689.

9. McCabe, M., Smith, F. P., Goldberg, D., Macdonald, J., Woolley, P. V., Warren, R. Division of Medical Oncology, Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, D.C. 1988. „Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy“. Investigational New Drugs 6:243–246.

10. Vinciguerra, V., Moore, T., Brennan. E. 1988. „Inhalation marijuana as an antiemetic for cancer chemotherapy“. New York State Journal of Medicine 88:525–527.

11. Chan, H. S., Correia, J. A., MacLeod, S. M. 1987. „Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial“. Pediatrics 79:946–952.

12. Priestman, S. G., Priestman, T. J., Canney, P. A. 1987. „A double-blind randomized cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea“. Clin Radiol. 38:543–544.

13. Crawford, S. M., Buckman, R. 1986. „Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: A double-blind study“. Med Oncol Tumor Pharmacother. 3(1):39–42.

14. Dalzell, A. M., Bartlett, H., Lilleyman, J. S. 1986 (May). „Nabilone: An alternative antiemetic for cancer chemotherapy“. Arch Dis Child. 61(5):502–505.

15. Pomeroy, M., Fennelly, J. J., Towers, M. 1986. „Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis“. Cancer Chemother Pharmacol 17(3):285–288.

16. Niiranen, A., Mattson, K. 1985 (Aug). „A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy“. American Journal of Clinical Oncology 8(4):336–340.

17. Ahmedzai, S., Carlyle, D. L., Calder, I. T., Moran, F. 1983 (Nov). „Antiemetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy“. Br J Cancer 48(5):657–663.

18. George, M., Pejovic, M. H., Thuaire, M., Kramar, A., Wolff, J. P. 1983. „Randomized comparative trial of a new anti-emetic, nabilone, in cancer patients treated with cisplatin“. Biomed Pharmacother. 37(1):24–27.

19. Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., Welsh, J., Stuart, F., Sangster, G., Kaye, S., Charlton, D., et al. 1983 (Aug). „A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy“. European Journal for Cancer and Clinical Oncology 19(8):1087–1090.

20. Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, J., Sarna, G., Jamison, K. 1982. „Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine“. Cancer 50:636–645.

21. Johansson, R., Kilkku, P., Groenroos, M. 1982 (Dec). „A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy“. Cancer Treat Rev. 9 Suppl B:25–33.

22. Jones, S. E., Durant, J. R., Greco, F. A., Robertone, A. 1982 (Dec). „A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting“. Cancer Treat Rev. 9 Suppl B:45–48.

23. Orr, L. E., McKernan, J. F. 1981. „Antiemetic effect of delta9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine“. J Clin Pharmacol 21:76S–80S.

24. Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., Dean, J. C., Furnas, B., Williams, S. D., Leigh, S. A., Dorr, R. T., Moon, T. E. 1979 (Jun 7). „Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy“. N Engl J Med. 300(23):1295–1297.

25. Sallan, Stephen E., M.D., Norman E. Zinberg, M.D., Emil Frei III, M.D. 1975. „Antiemetic effect of Delta-9-Tetrahydrocannabinol in patients receiving cancer chemotherapy“. N Engl J Med 293:795–797.

Kinetóza

1. Turner, M., Griffin, M. J. 1999. „Motion sickness in public road transport: Passenger behavior and susceptibility“. Ergonomics 42:444–461.

2. Cluny, N. L., Naylor, R. J., Whittle, B. A., Javid, F. A. 2008 (Aug). „The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus“. Basic Clin Pharmacol Toxicol. 103(2):150–156.

3. Chouker, Alexander, Ines Kaufmann, Simone Kreth, Daniela Hauer, Matthias Feuerecker, Detlef Thieme, Michael Vogeser, Manfred Thiel, Gustav Schelling. 2010. „Motion sickness, stress and the endocannabinoid system“. PLoS One. 5(5).

4. Grace, William J., M.D., Graham, David T., M.D. Dept. of Medicine of the New York Hospital–Cornell Medical Center. 1952 (Jul 1). „Relationship of specific attitudes and emotions to certain bodily diseases“. Psychosomatic Medicine 14(4):243–251.

5. Chouker, Alexander, et al. 2010. „Motion sickness, stress and the endocannabinoid system“. Viz pozn. 3.

6. Crockett, S. L., Schühly, W., Bauer, R. 2007. „Pflanzliche antiemetika. Inhaltsstoffe, molekulare wirkmechanismen und klinische evidenz“. Pharm Unserer Zeit. 36(5):381–388.

7. Spolková republika Německo. Monographien der E-Kommission (Phyto-Therapie). 380 monografií. Terapeutický průvodce herbální medicínou hodnotící bezpečnost a účinnost léčivých rostlin pro účely lékařské preskripce v Německu. Publikováno mezi roky 1984 a 1994 v Bundesanzeiger (oficiálním věstníku ministerstva spravedlnosti Spolkové republiky Německo). Kopie monografií jsou dostupné v Heilpflanzen-Welt Bibliothek: http://buecher.heilpflanzen-welt.de/BGA-Commission-E-Monographs/.

8. Schmid, R., Schick, T., Steffen, R., Tschopp, A., Wilk, T. 1994 (Dec 1). „Comparison of seven commonly used agents for prophylaxis of seasickness“. J Travel Med. 1(4):203–206.

9. Nanthakomon, T., Pongrojpaw, D. 2006 (Oct). „The efficacy of ginger in prevention of postoperative nausea and vomiting after major gynecologic surgery“. J Med Assoc Thai. 89 Suppl 4:S130–136.

10. Chittumma, P., Kaewkiattikun, K., Wiriyasiriwach, B. 2007 (Jan). „Comparison of the effectiveness of ginger and vitamin B6 for treatment of nausea and vomiting in early pregnancy: A randomized double-blind controlled trial“. J Med Assoc Thai. 90(1):15–20.

Péče o rány (obecně)

1. Radwan, S., El-Essawy, A., Sarhan, M. M. 1984. „Experimental evidence for the occurrence in honey of specific substances active against microorganisms“. Zentral Microbiol. 139:249–255.

Ibrahim, A. S. 1985. „Antibacterial action of honey“. Bull Islam Med. 1:363–365.

Jeddar, A., Kharsany, A., Ramsaroop, U. G., Bhamjee, A., Hafejee, I. E., Moosa, A. 1985. „The antibacterial action of honey“. South Afri Med J. 67:257–258.

Molan, P. C., Smith, I. M., Reid, G. M. 1988. „A comparison of the antibacterial activities of some New Zealand honeys“. Journal of Agricultural Research 27:252–256.

Subramanyam, M. 1991. „Tropical application of honey in treatment of burns“. Br J Surg. 78:497–498.

2. Kubánské ministerstvo veřejného zdraví, Havana. 1992. Guia Terapeutica Dispensarial de Fitofarmacos y Apifarmacos. Terapeutický průvodce rostlinnými a medovými farmaky.

3. Callaway, J., Schwab, U., Harvima, I., Halonen, P., Mykkanen, O., Hyvonen, P., Jarvinen, T. 2005 (Apr). „Efficacy of dietary hempseed oil in patients with atopic dermatitis“. J Dermatolog Treat. 16(2):87–94.

Fraktury kostí

1. Joshua M. Abzug, M.D., Aaron Johnson, M.D., M.S., Brandon S. Schwartz, MPH. „Inappropriate Splint Application for Pediatric Fractures in the Emergency Department and Urgent Care Environment“. Prezentováno na Národní konferenci Americké pediatrické akademie (San Diego, 2014).

2. Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., Essig, J., Erxlebe, E., Bab, I., Kubisch, C., de Vernejoul, M. C., Zimmer, A. 2005 (Nov 15). „Cannabinoid receptor type 2 gene is associated with human osteoporosis“. Oddělení psychiatrie centra Life & Brain, Univerzita v Bonnu (Německo). Hum Mol Genet. 14(22):3389-3396.

3. Orr Ofek, Meliha Karsak, Nathalie Leclerc, Meirav Fogel, Baruch Frenkel, Karen Wright, Joseph Tam, Malka Attar-Namdar, Vardit Kram, Esther Shohami, Raphael Mechoulam, Andreas Zimmer, Itai Bab. 2006 (Jan 17).„Peripheral cannabinoid receptor, CB2, regulates bone mass“. PNAS 103(3):696-701. Kostní laboratoř Hebrejské univerzity v Jeruzalémě (Bone Laboratory, Hebrew University of Jerusalem, P. O. B. 12272, Jerusalem 91120, Israel).

4. Bab, I., Zimmer, A., Melamed, E. 2009. „Cannabinoids and the skeleton: from marijuana to reversal of bone loss“. Ann Med. 41(8):560-567. Kostní laboratoř Hebrejské univerzity v Jeruzalémě (Izrael).

5. Kogan, N. M., Melamed, E., Wasserman, E., Raphael, B., Breuer, A., Stok, K. S., Sondergaard, R., Escudero, A. V., Baraghithy, S., Attar-Namdar, M., Friedlander-Barenboim, S., Mathavan, N., Isaksson, H., Mechoulam, R., Müller, R., Bajayo, A., Gabet, Y., Bab, I. 2015 (Oct). „Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts“. J Bone Miner Res. 30(10):1905–13.

Pooperační rány

1. Burstein, Sumner H., Zurier, Robert B. 2009 (Mar). „Cannabinoids, endocannabinoids, and related analogs in inflammation“. AAPS J. 11(1):109–119.

Poranění míchy

1. Obratlů je ve skutečnosti 33. Křížová kost se skládá z pěti srostlých křížových obratlů, mezi nimiž nejsou ploténky. Kostrč tvoří čtyři srostlé obratle, mezi nimiž také nejsou ploténky.

2. Dunn, M., Davis, R. 1974 (Nov). „The perceived effects of marijuana on spinal cord injured males“. Paraplegia. 12(3):175.

3. Hagenbach, U., Luz, S., Ghafoor, N., Berger, J. M., Grotenhermen, F., Brenneisen, R., Mader, M. 2007 (Aug). „The treatment of spasticity with Delta(9)-tetrahydrocannabinol in persons with spinal cord injury“. Spinal Cord. 45(8):551–562.

4. Kogel, R. W., Johnson, P. B., Chintam, R., Robinson, C. J., Nemchausky, B. A. 1995 (Oct). „Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative“. Am J Ther. 2(10):799–805.

5. Maurer, M., Henn, V., Dittrich, A., Hofmann, A. 1990. „Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial“. Eur Arch Psychiatry Clin Neurosci. 240(1):1–4.

6. Malec, J., Harvey, R. F., Cayner, J. J. 1982 (Mar). „Cannabis effect on spasticity in spinal cord injury“. Arch Phys Med Rehabil. 63(3):116–118.